ZELTIQ Aesthetics (ZLTQ) 10-K26 Feb 142013 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2013	Feb. 20, 2014	Jun. 28, 2013
Document and Entity Information: [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'Zeltiq Aesthetics Inc	'	'
Entity Central Index Key	'0001415336	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Common Stock, Shares Outstanding	'	37,210,444	'
Entity Public Float	'	'	$115,299,901

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
ASSETS	'	'
Cash and cash equivalents	$25,798	$22,876
Short-term investments	18,840	22,563
Accounts receivable, net	10,221	7,133
Inventory	8,406	10,871
Prepaid expenses and other current assets	4,368	3,600
Total current assets	67,633	67,043
Long-term investments	11,442	13,141
Restricted cash	331	469
Property and equipment, net	2,158	2,336
Intangible asset, net	6,481	7,181
Other assets	9	99
Total assets	88,054	90,269
LIABILITIES AND STOCKHOLDERSâ€™ EQUITY	'	'
Accounts payable	5,165	4,976
Accrued liabilities	18,364	11,076
Deferred revenue	1,674	1,401
Total current liabilities	25,203	17,453
Other non-current liabilities	275	236
Total liabilities	25,478	17,689
Commitments and contingencies (Note 8)	'	'
STOCKHOLDERSâ€™ EQUITY:	'	'
Preferred stock, $0.01 par value: 50,000,000 shares authorized and no shares issued and outstanding at December 31, 2013 and December 31, 2012	0	0
Common stock, $0.001 par value: 500,000,000 shares authorized at December 31, 2013 and December 31, 2012; 37,038,374 and 35,852,105 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	41	39
Additional paid-in capital	195,507	186,287
Accumulated other comprehensive income	87	8
Accumulated deficit	-133,059	-113,754
Total stockholdersâ€™ equity	62,576	72,580
Total liabilities and stockholdersâ€™ equity	$88,054	$90,269

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (dollars per share)	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	37,038,374	35,852,105
Common stock, shares outstanding	37,038,374	35,852,105

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Revenue	$111,626	$76,194	$68,144
Cost of revenue	34,189	25,506	26,101
Gross profit	77,437	50,688	42,043
Operating expenses:	'	'	'
Research and development	17,090	12,693	10,488
Sales and marketing	63,185	51,167	28,953
General and administrative	16,510	16,867	11,299
Total operating expenses	96,785	80,727	50,740
Loss from operations	-19,348	-30,039	-8,697
Interest income (expense), net	80	129	-93
Other income (expense), net	103	-92	-765
Loss before provision for income taxes	-19,165	-30,002	-9,555
Provision for income taxes	140	141	48
Net loss	-19,305	-30,143	-9,603
Cumulative dividends on convertible preferred stock	0	0	-5,099
Net loss attributable to common stockholders	($19,305)	($30,143)	($14,702)
Net loss per share attributable to common stockholders, basic and diluted (dollars per share)	($0.53)	($0.87)	($1.96)
Weighted average shares of common stock outstanding used in computing net loss attributable to common stockholders, basic and diluted	36,209,051	34,776,380	7,506,282

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Net loss	($19,305)	($30,143)	($9,603)
Other comprehensive income, net of tax:	'	'	'
Foreign currency translation adjustments	77	0	0
Changes in unrealized gains on available-for-sale securities	2	8	0
Other comprehensive income, net of tax	79	8	0
Comprehensive loss	($19,226)	($30,135)	($9,603)

Consolidated_Statements_of_Con

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Note Receivable From Stockholder [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
In Thousands, except Share data, unless otherwise specified	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Note Receivable From Stockholder [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2010	($84,493)	$93,888	$4	$0	($245)	$0	($84,252)
Balance, shares at Dec. 31, 2010	'	23,381,764	1,216,167	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'
Issuance of common stock upon exercise of stock options	592	'	1	591	'	'	'
Issuance of common stock upon exercise of stock options, shares	'	'	553,023	'	'	'	'
Issuance of stock for services	34	'	0	34	'	'	'
Issuance of stock for services, shares	'	'	11,495	'	'	'	'
Revision to correct prior accretion on convertible preferred stock	12,724	-12,724	'	2,480	'	'	10,244
Exercise of common stock warrants for cash	3	'	'	3	'	'	'
Exercise of common stock warrants for cash, shares	'	'	58,159	'	'	'	'
Conversion of preferred stock into common stock upon initial public offering	81,164	-81,164	24	81,140	'	'	'
Conversion of preferred stock into common stock upon initial public offering, shares	'	23,381,764	24,415,965	'	'	'	'
Reclassification of preferred stock warrant liability into additional paid-in capital upon initial public offering	921	'	'	921	'	'	'
Issuance of common stock in initial public offering, net of underwriter discount of $7,046 and issuance costs of $2,931	90,682	'	8	90,674	'	'	'
Issuance of common stock in initial public offering, net of underwriter discount of $7,046 and issuance costs of $2,931, shares	'	'	7,743,000	'	'	'	'
Stock-based compensation	2,279	'	'	2,279	'	'	'
Change in unrealized gain (loss) on marketable securities, net of tax	0	'	'	'	'	'	'
Currency translation adjustments, net of tax	0	'	'	'	'	'	'
Net loss	-9,603	'	'	'	'	'	-9,603
Comprehensive loss	-9,603	'	'	'	'	'	'
Balance at Dec. 31, 2011	94,303	0	37	178,122	-245	0	-83,611
Balance, shares at Dec. 31, 2011	'	0	33,997,809	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'
Issuance of common stock upon exercise of stock options	2,669	'	2	2,667	'	'	'
Issuance of common stock upon exercise of stock options, shares	1,612,233	'	1,612,233	'	'	'	'
Issuance of common stock in connection with ESPP	497	'	0	497	'	'	'
Issuance of common stock in connection with ESPP, shares	'	'	133,363	'	'	'	'
Issuance of stock for services	12	'	0	12	'	'	'
Issuance of stock for services, shares	'	'	1,741	'	'	'	'
Conversion of preferred stock into common stock upon initial public offering	0	'	'	'	'	'	'
Reclassification of preferred stock warrant liability into additional paid-in capital upon initial public offering	0	'	'	'	'	'	'
Proceeds for repayment of notes receivable from a stockholder	245	'	'	'	245	'	'
Issuance of common stock upon vesting of RSUs	0	'	0	'	'	'	'
Issuance of common stock upon vesting of RSUs, shares	'	'	106,959	'	'	'	'
Stock-based compensation	4,989	'	'	4,989	'	'	'
Change in unrealized gain (loss) on marketable securities, net of tax	8	'	'	'	'	8	'
Currency translation adjustments, net of tax	0	'	'	'	'	'	'
Net loss	-30,143	'	'	'	'	'	-30,143
Comprehensive loss	-30,135	'	'	'	'	'	'
Balance at Dec. 31, 2012	72,580	0	39	186,287	0	8	-113,754
Balance, shares at Dec. 31, 2012	'	0	35,852,105	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'
Issuance of common stock upon exercise of stock options	2,647	'	2	2,645	'	'	'
Issuance of common stock upon exercise of stock options, shares	791,198	'	791,198	'	'	'	'
Issuance of common stock in connection with ESPP	791	'	'	791	'	'	'
Issuance of common stock in connection with ESPP, shares	'	'	188,467	'	'	'	'
Issuance of common stock upon vesting of RSUs, shares	'	'	292,265	'	'	'	'
Common stock traded for employee tax obligation	-876	'	'	-876	'	'	'
Common stock traded for employee tax obligation, shares	'	'	-85,661	'	'	'	'
Conversion of preferred stock into common stock upon initial public offering	0	'	'	'	'	'	'
Reclassification of preferred stock warrant liability into additional paid-in capital upon initial public offering	0	'	'	'	'	'	'
Stock-based compensation	6,660	'	'	6,660	'	'	'
Change in unrealized gain (loss) on marketable securities, net of tax	2	'	'	'	'	2	'
Currency translation adjustments, net of tax	77	'	'	'	'	77	'
Net loss	-19,305	'	'	'	'	'	-19,305
Comprehensive loss	-19,226	'	'	'	'	'	'
Balance at Dec. 31, 2013	$62,576	$0	$41	$195,507	$0	$87	($133,059)
Balance, shares at Dec. 31, 2013	'	0	37,038,374	'	'	'	'

Consolidated_Statements_of_Con1

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011
Statement of Stockholders' Equity [Abstract]	'
Issuance of common stock in initial public offering, underwriter discount	$7,046
Issuance of common stock in initial public offering, issuance costs	$2,931

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($19,305)	($30,143)	($9,603)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	1,729	1,602	826
Stock-based compensation	6,660	4,989	2,279
Change in fair value of preferred stock warrant liability	0	0	664
Deferred income tax provision (benefit)	19	-66	0
Amortization of debt discount	0	0	49
Amortization of investment premium	343	212	0
(Recovery from) provision for doubtful accounts receivable	-12	290	0
Issuance of common stock for services	0	12	34
Provision for excess and obsolete inventory	22	183	0
Loss on disposal and write-off of property and equipment	2	192	291
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-3,064	-2,482	-4,328
Inventory	2,465	-6,578	-2,312
Prepaid expenses and other assets	-693	-1,240	-1,400
Deferred revenue, net of deferred costs	267	1,026	-316
Accounts payable, accrued and other non-current liabilities	7,486	5,377	3,520
Net cash used in operating activities	-4,081	-26,626	-10,296
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchase of investments	-31,591	-58,658	0
Sale of investments	11,143	9,250	0
Maturity of investments	25,528	13,500	0
Purchase of property and equipment	-834	-1,385	-1,575
Purchase of intangible asset	0	0	-7,000
Restricted cash	138	-214	170
Net cash provided by (used in) investing activities	4,384	-37,507	-8,405
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Repayment of notes payable	0	-310	-1,335
Proceeds from issuance of common stock in initial public offering, net of underwriter discount and issuance costs	0	0	90,682
Proceeds from repayment of note receivable by a stockholder	0	245	0
Proceeds from issuance of common stock upon exercise of stock options and issuance of ESPP shares	3,438	3,166	595
Tax payments related to shares withheld for vested restricted stock units	-876	0	0
Net cash provided by financing activities	2,562	3,101	89,942
Effect of exchange rate on cash and cash equivalents	57	0	0
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,922	-61,032	71,241
CASH AND CASH EQUIVALENTSâ€”Beginning of period	22,876	83,908	12,667
CASH AND CASH EQUIVALENTSâ€”End of period	$25,798	$22,876	$83,908

The_Company_And_Basis_Of_Prese

The Company And Basis Of Presentation	12 Months Ended
The Company And Basis Of Presentation	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
The Company and Basis of Presentation	'
	The Company and Basis of Presentation
	ZELTIQ Aesthetics, Inc. (“we” or the “Company”) was incorporated in the state of Delaware on March 22, 2005. The Company was founded to develop and commercialize a non-invasive product for the selective reduction of fat. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes precisely controlled cooling to reduce the temperature of fat cells in the treated area, which leads to fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. The Company generates revenue from sales of our CoolSculpting system and from sales of consumables to our customers.
	In August 2011, the Company incorporated ZELTIQ Limited as a wholly-owned subsidiary in the United Kingdom to serve as its sales office for direct sales in Europe.
	Reverse Stock Split
	On October 13, 2011, the Company filed a certificate of amendment to the Company’s amended and restated certificate of incorporation that effected a reverse stock split of the Company’s common stock in which each 3.670069 shares of common stock outstanding or held in treasury immediately prior to such time was combined into one share of common stock. The par value of the common stock remained $0.001 per share. Accordingly, all share and per share amounts for all periods presented in these consolidated financial statements and notes thereto, have been adjusted retroactively, where applicable, to reflect this reverse stock split.
	Initial Public Offering
	On October 24, 2011, the Company completed its initial public offering, or IPO, of 8,050,000 shares of common stock at an offering price of $13.00 per share, of which 7,743,000 shares were sold by the Company and 307,000 shares were sold by existing stockholders. The Company received net proceeds of approximately $90.7 million, after deducting underwriting discounts, commissions and offering related transaction costs. In connection with the IPO, the Company’s outstanding shares of convertible preferred stock were automatically converted into 24,415,965 shares of common stock.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

Based on an evaluation of economic facts and circumstances together with the functional currency analysis prescribed in Accounting Standards Codification Topic 830, Foreign Currency Matters, on October 1, 2013, we changed the functional and reporting currency of our foreign subsidiary from the U.S. Dollar to the Great Britain Pound. Such change did not have a material impact on the consolidated financial statements of the Company.

All assets and liabilities of these foreign operations are translated to U.S. Dollars at current period end exchange rates, and revenues and expenses are translated to U.S. Dollars using average exchange rates in effect during the period. The gains and losses from the foreign currency translation of this subsidiary's financial statements are included as a separate component of stockholders' equity under "Accumulated other comprehensive income". Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in other income (expense), net.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. The primary estimates underlying the Company's financial statements include the value of revenue elements, product warranty, inventory valuation, allowance for doubtful accounts receivable, assumptions regarding variables used in calculating the fair value of the Company's equity awards, fair value of investments, useful lives of intangibles, income taxes and contingent liabilities. Actual results could differ from those estimates.

Significant Risks and Uncertainties

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals. If the Company fails to adhere to ongoing FDA Quality System Regulation, the FDA may withdraw its market clearance or take other action. The Company relies on sole-source suppliers to manufacture some of the components used in its product. The Company's manufacturers and suppliers may encounter supply interruptions or problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA's Quality System Regulation, equipment malfunction and environmental factors, any of which could delay or impede the Company's ability to meet demand.

Concentration of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, marketable securities and trade receivables. Our cash equivalents and marketable securities are held in safekeeping by large, credit worthy financial institutions. The Company invests our excess cash primarily in U.S. banks, government and agency bonds, money market funds and corporate obligations. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on our deposits of cash and cash equivalents.

The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management's assessment of the collectability of specific customer accounts and the aging of the related invoices, and represents our best estimate of probable credit losses in our existing trade accounts receivable. The Company did not have an allowance for doubtful accounts as of December 31, 2013. At December 31, 2012, the Company's allowance for doubtful accounts was $0.3 million.

The allowance for doubtful accounts consisted of the following activity for fiscal years ended December 31, 2013, 2012 and 2011 (in thousands):

Description

Balance at Beginning of Year

Additions

Reductions

Balance at End of Year

Year ended December 31, 2011

Year ended December 31, 2012

329

330

Year ended December 31, 2013

330

389

—

As of December 31, 2013 and 2012, no individual customer accounted for 10% or more of the Company's accounts receivable. Furthermore, no individual customer accounted for greater than 10% of total revenue during the years ended December 31, 2013, 2012 and 2011, respectively.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

Investments

The Company invests its excess cash balances primarily in certificates of deposit, commercial paper, corporate bonds, and U.S. Government agency securities. Investments with original maturities greater than 90 days that mature less than one year from the consolidated balance sheet date are classified as short-term investments. The Company classifies all of its investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of accumulated other comprehensive income (loss) in stockholders' equity. Realized gains and losses from maturities of all such securities are reported in earnings and computed using the specific identification cost method. Realized gains or losses and charges for other-than-temporary declines in value, if any, on available-for-sale securities are reported in other income (expense), net as incurred. The Company periodically evaluates these investments for other-than-temporary impairment.

Inventory

Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or market, computed on a standard cost basis. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated.

The useful lives of the property and equipment are as follows:

Lab equipment, tooling, and molds

5 years

Computer equipment

3 years

Computer software

3 years

Furniture and fixtures

5 years

Vehicles

5 years

Leasehold improvements

Shorter of lease term or estimated useful life

Capitalized Software

The Company capitalizes costs associated with customized internal-use software systems that have reached the application development stage and meet recoverability tests. Such capitalized costs mainly include external direct costs utilized in developing or obtaining the applications. Capitalization of such costs begins when the preliminary project stage is complete and ceases at the point in which the project is substantially complete and is ready for its intended purpose. The capitalized costs associated with internal-use software are depreciated on a straight-line basis over each asset's estimated useful life, which is generally three years.

Restricted Cash

At December 31, 2013 and 2012, cash of $0.3 million and $0.5 million, respectively, was restricted from withdrawal and held by banks in the form of certificates of deposit. At December 31, 2013 and 2012, the certificates of deposit were held as collateral for the facility lease agreement in Pleasanton, California, statutory French VAT requirements and for our United Kingdom banking facilities.

Intangible Asset

The intangible asset consists of an exclusive license agreement for commercializing patents and other technology. All milestone payments subsequent to the date of the FDA approval are capitalized as purchased technology when paid, and are subsequently amortized into cost of revenue using the straight-line method over the estimated remaining useful life of the technology, not to exceed the term of the agreement or the life of the patent.

Impairment of Long-lived Assets

The Company reviews property and equipment and the intangible asset for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the assets' fair value determined using the projected discounted future net cash flows arising from the asset. Through December 31, 2013, there have been no such impairments.

Revenue Recognition

The Company’s revenue is derived from the sales of the CoolSculpting system, consisting of a control unit and applicators, and from the sale of cycles in the form of consumable procedure packs, each of which includes consumable CoolGels and CoolLiners and a disposable computer cartridge that the Company markets as the CoolCard. Embedded software exists in the CoolCard product to permit the Company’s customers to perform a fixed number of CoolSculpting procedures, or cycles. This software is not marketed separately from the CoolSculpting system or from the CoolCard. Rather, the functionality that the software provides is part of the overall CoolCard product. The CoolSculpting system is marketed as a non-invasive aesthetic device for the reduction of fat, not for its embedded software attributes included in the CoolCard that enable its use. The Company does not provide rights to upgrades and enhancements or post-contract customer support for the embedded software. In addition, the Company does not incur significant software development costs or capitalize its software development costs. Based on this assessment, the Company considers the embedded software in the CoolCard incidental to the CoolCard product as a whole and determined that revenue recognition should not be governed by the provisions of Topic 985 of the FASB Accounting Standards Codification, or ASC. The Company earns revenue from the sale of its products to its customers and to distributors. The Company recognizes revenue when persuasive evidence of an arrangement exists, transfer of title to the customer has occurred, the sales price is fixed or determinable, and collectability is probable. Revenue is deferred in the event that any of the revenue recognition criteria is not met.

Persuasive Evidence of an Arrangement. The Company uses contracts or customer purchase orders to determine the existence of an arrangement.

Transfer of title. Our standard terms generally specify that title transfers upon shipment to the customer. The Company uses third party shipping documents to verify that title has transferred.

Sales Price Fixed or Determinable. The Company assesses whether the sales price is fixed or determinable at the time of the transaction. Sales prices are documented in the executed sales contract or purchase order received prior to shipment. The Company’s standard terms do not allow for trial or evaluation periods, rights of return or refund, payments contingent upon the customer obtaining financing or other terms that could impact the customer’s obligation.

Collectability. The Company assesses whether collection is reasonably assured based on a number of factors, including the customer’s past transaction history and credit worthiness.

Multiple-Element Arrangements. Typically, all products sold to a customer are delivered at the same time. If a partial delivery occurs as authorized by the customer, the Company allocates revenue to the various products based on their vendor-specific objective evidence of fair value, or VSOE, if VSOE exists according to ASC 605-25 as the basis of determining the relative selling price of each element. If VSOE does not exist, the Company may use third party evidence of fair value, or TPE, to determine the relative selling price of each element. If neither VSOE nor TPE exists, the Company may use management’s best estimate of the sales price, or ESP, of each element to determine the relative selling price. The relative selling prices for control units, applicators, CoolCards and extended warranty are based on established price lists and separate, stand-alone sales of these elements. The Company establishes best estimates within a range of selling prices considering multiple factors including, but not limited to, factors such as size of transaction, pricing strategies and market conditions. The Company believes the use of the ESP allows revenue recognition in a manner consistent with the underlying economics of the transaction. The Company’s products do not require maintenance or support.

Accruals for Customer Programs

The Company records an accrued liability for cooperative marketing arrangements and customer incentive programs. The estimated cost of these programs is recorded as a reduction of revenue or as an operating expense, if the Company receives a separately identifiable benefit from the customer and can reasonably estimate the fair value of that benefit. Significant management judgment and estimates must be used to determine the cost of these programs in any accounting period.

Cooperative Marketing Arrangements. The Company offers cooperative marketing programs to its North American customers, allowing the customer to receive partial reimbursement for qualifying advertising expenditures which promote the Company's product and brand. Customer participation, as well as reimbursement amounts, is predicated upon purchase levels of CoolCards. The objective of these arrangements is to encourage advertising and promotional events to increase sales of the Company's products. Accruals for these marketing arrangements are recorded at the time of sale, or time of commitment, based on the related program parameters, review of related advertising and historical experience.

Customer Incentive Programs. The Company's customer incentive program consists of rebates for our North American customers based on purchase levels of CoolCards. Estimated costs of consumer rebates and similar incentives are recorded at the time the incentive is offered, based on the specific terms and conditions of the program.

Cost of Revenue

Cost of revenue consists primarily of cost of finished and semi-finished products purchased from our third-party suppliers, labor, material, and overhead involved in our internal manufacturing processes, technology amortization and royalty fees and cost of product warranty. In the event that a revenue transaction is deferred, the corresponding cost associated with the transaction will also be deferred.

Shipping and Handling

Shipping and handling costs charged to customers are recorded as revenue. Shipping costs are included in cost of revenue.

Research and Development

Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, and allocated facilities costs for employees and contractors engaged in research, clinical studies, regulatory affairs, and development. The Company expenses all research and development costs in the periods in which they are incurred.

Advertising costs

The cost of advertising and media is expensed as incurred. For the years ended December 31, 2013, 2012 and 2011, advertising costs totaled $8.9 million, $12.0 million and $1.9 million, respectively.

Product Warranty

Effective in the second quarter of 2013, the Company provides a standard limited warranty on its products of generally one year for both control units and applicators for its direct customers. Prior to this change, the Company provided a standard limited warranty on its products of generally three years for control units and one year for applicators, while for direct customers in Europe, the Company offered a one year standard warranty on control units. For indirect customers in international markets the Company provides a standard limited warranty on its products of generally three years for control units and one year for applicators.

The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based upon historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. The Company bases product warranty costs on related freight, material, technical support labor, and overhead costs. The estimated product warranty costs are assessed by considering historical costs and applying the experienced failure rates to the outstanding warranty period for products sold. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, and average repair costs, including freight, material, technical support labor, and overhead costs, for products returned under warranty.

The Company offers an extended warranty of up to two years on both our CoolSculpting control units and CoolSculpting applicators. The Company recognizes the revenue from the sale of an extended warranty over the extended warranty coverage period. Our revenue and related obligations from sale of extended warranties to date has not been significant.

Stock-Based Compensation

The Company maintains incentive plans under which incentive and nonqualified stock options are granted primarily to employees and non-employee consultants.

Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The fair value of stock-based awards to employees is estimated using the Black-Scholes option pricing model. The Company estimates its forfeiture rate based on an analysis of its actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate assumption based on actual forfeitures, analysis of employee turnover, and other related factors.

Stock-based compensation expense related to stock options granted to non-employees is recognized as the stock options are earned. The awards generally vest ratably over the time period the Company expects to receive services from the non-employee. The fair values attributable to these options are amortized over the service period and the unvested portion of these options is remeasured at each vesting date.

Income Taxes

The Company utilizes the asset and liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse and for operating losses and tax credit carryforwards. The Company estimates our provision for income taxes and amounts ultimately payable or recoverable in multiple tax jurisdictions around the world. Estimates involve interpretations of regulations and are inherently complex. Resolution of income tax treatments in individual jurisdictions may not be known for many years after completion of any fiscal year. The Company is required to evaluate the realizability of our deferred tax assets on an ongoing basis to determine whether there is a need for a valuation allowance with respect to such deferred tax assets. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considers all available positive and negative evidence giving greater weight to our recent cumulative losses and our ability to carryback losses against prior taxable income and, commensurate with objective verifiability, the forecast of future taxable income including the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies.

The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement. The Company reports a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company adjusts these reserves in light of changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the provision for income taxes in the period in which such determination is made. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate, as well as the related net interest. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax provision. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheet.

The Company files annual income tax returns in multiple taxing jurisdictions around the world. A number of years may elapse before an uncertain tax position is audited and finally resolved. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that our reserves for income taxes reflect the most likely outcome. The Company adjusts these reserves, as well as the related interest, in light of changing facts and circumstances. Settlement of any particular position could require the use of cash.

Net Loss Per Share

Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities outstanding during the period, including options, restricted stock units, stock issuable pursuant to the employee stock purchase plan, warrants, and convertible preferred stock. Basic and diluted net loss per share attributable to common stockholders was the same for all periods presented as the inclusion of all potentially dilutive securities outstanding were anti-dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss are the same for each period presented.

Comprehensive Income (Loss)

Accumulated other comprehensive income includes foreign currency translation adjustments and unrealized gains (losses) on available-for-sale securities net of tax, the impact of which has been excluded from earnings and reflected as components of stockholders' equity.

Components of accumulated other comprehensive income was as follows (in thousands):

December 31,

2013

2012

Cumulative translation adjustments

—

Unrealized gain on marketable securities, net of tax

Accumulated other comprehensive income

Recent Accounting Pronouncements

On February 5, 2013, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. This guidance is the culmination of the FASB's redeliberation on reporting reclassification adjustments from accumulated other comprehensive income. The Company adopted this guidance effective during the first quarter of 2013 and such adoption did not have a material impact on the Company's consolidated financial statements.

Fair_Value_Of_Financial_Instru

Fair Value Of Financial Instruments	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
	Level 1—Quoted prices in active markets for identical assets or liabilities.
	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company did not hold any Level 3 assets or liabilities at December 31, 2013.
	The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.
	The Company classifies its cash equivalents and investments within Level 1 and Level 2, as it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs. The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):



		As of December 31, 2013
		Level 1		Level 2		Level 3		Fair Value
	Financial Assets
	Cash equivalents:
	Money market funds	$	12,796	$	—	$	—	$	12,796

	Short-term investments:
	U.S. Agency securities	—		6,772		—		6,772

	U.S. Treasury	—		1,001		—		1,001

	Corporate bonds	—		8,870		—		8,870

	Commercial paper	—		999		—		999

	Certificates of deposit	1,198		—		—		1,198

	Long-term investments:
	U.S. Agency securities	—		6,956		—		6,956

	U.S. Treasury	—		1,014		—		1,014

	Corporate bonds	—		2,795		—		2,795

	Certificates of deposit	$	677	$	—	$	—	$	677

		$	14,671	$	28,407	$	—	$	43,078




		As of December 31, 2012
		Level 1		Level 2		Level 3		Fair Value
	Financial Assets
	Cash equivalents:
	Money market funds	$	18,274	$	—	$	—	$	18,274

	Short-term investments:
	U.S. Agency securities	—		11,077		—		11,077

	Corporate bonds	—		8,417		—		8,417

	Commercial paper	—		1,998		—		1,998

	Certificates of deposit	1,071		—		—		1,071

	Long-term investments:
	U.S. Agency securities	—		7,753		—		7,753

	Corporate bonds	—		5,388		—		5,388

		$	19,345	$	34,633	$	—	$	53,978


During the years ended December 31, 2013 and 2012, the Company did not have any transfers of financial assets measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3. The Company did not hold any Level 3 assets or liabilities as of December 31, 2013, and December 31, 2012.

The carrying amounts of the Company’s cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities.

Balance_Sheet_Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2013
Balance Sheet Related Disclosures [Abstract]	'
Balance Sheet Components	'
	Balance Sheet Components
	Investments
	The Company's short-term and long-term investments as of December 31, 2013 are as follows (in thousands):


	Short-term
		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	6,771		$	2	$	(1	)	$	6,772

	U.S. Treasury	1,000			1		—			1,001

	Corporate bonds	8,867			3		—			8,870

	Commercial paper	999			—		—			999

	Certificates of deposit	1,198			—		—			1,198

	Total	$	18,835		$	6	$	(1	)	$	18,840



	Long-term
		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	6,957		$	2	$	(3	)	$	6,956

	U.S. Treasury	1,013			1		—			1,014

	Corporate bonds	2,790			5		—			2,795

	Certificates of deposit	677			—		—			677

	Total	$	11,437		$	8	$	(3	)	$	11,442


	The Company's short-term and long-term investments as of December 31, 2012, are as follows (in thousands):


	Short-term
		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	11,071		$	6	$	—		$	11,077

	Corporate bonds	8,414			3		—			8,417

	Commercial paper	1,998			—		—			1,998

	Certificates of deposit	1,071			—		—			1,071

	Total	$	22,554		$	9	$	—		$	22,563


	Long-term
		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	7,750		$	3	$	—		$	7,753

	Corporate bonds	5,392			1		(5		)	5,388

	Total	$	13,142		$	4	$	(5	)	$	13,141


	For the years ended December 31, 2013 and December 31, 2012, gains or losses realized on the sale of investments were insignificant.

	The contractual maturities of the Company's short-term and long-term investments as of December 31, 2013, are as follows (in thousands):


	December 31, 2013
	Amortized Cost			Fair Value
Due in one year or less	$	18,835		$	18,840

Due in one year to five years	11,437			11,442

	$	30,272		$	30,282

When evaluating the investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below the amortized cost basis, review of current market liquidity, interest rate risk, the financial condition of the issuer, as well as credit rating downgrades. The Company believes that the unrealized losses are not other-than-temporary. The Company does not have a foreseeable need to liquidate the portfolio and anticipates recovering the full cost of the securities either as market conditions improve, or as the securities mature.

Inventory
Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or market, computed on a standard cost basis. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions.
The components of inventory consist of the following (in thousands):


	December 31,
	2013			2012
Raw materials	$	4,520		$	8,302

Finished goods	3,886			2,569

Total inventory	$	8,406		$	10,871

Property and equipment, net
Property and equipment, net comprised the following (in thousands):


	December 31,
	2013			2012
Lab equipment, tooling and molds	$	2,071		$	1,987

Computer software	1,562			1,243

Computer equipment	801			753

Leasehold improvements	743			636

Furniture and fixtures	334			288

Vehicles	35			35

Total property and equipment	5,546			4,942

Less: Accumulated depreciation and amortization	(3,594		)	(2,610		)
Construction in progress	206			4

Property and equipment, net	$	2,158		$	2,336


Depreciation expense for the years ended December 31, 2013, 2012 and 2011 was $1.0 million, $0.9 million and $0.7 million, respectively.
Accrued Liabilities
The following table shows the components of accrued liabilities (in thousands):


	December 31,
	2013			2012
Accrued payroll and employee related expenses	$	7,863		$	3,430

Accrued marketing expenses	3,739			3,287

Accrued royalty	2,458			1,343

Sales and other taxes payable	1,787			1,177

Accrued warranty	676			902

Accrued legal expenses	284			415

Other accrued liabilities	1,557			522

Total accrued liabilities	$	18,364		$	11,076


Product Warranty

The estimated product warranty accrual was as follows (in thousands):


	December 31,
	2013			2012
Balance at the beginning of the period	$	902		$	742

Accruals for warranties issued	197			869

Settlements of warranty claims	(423		)	(709		)
Balance at the end of the period	$	676		$	902

License_Agreement_With_Massach

License Agreement With Massachusetts General Hospital	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
License Agreement with Massachusetts General Hospital	'
	License Agreement with Massachusetts General Hospital

	In May 2005, the Company entered into an exclusive license agreement with the General Hospital Corporation, a not for profit Massachusetts corporation, which owns and operates the Massachusetts General Hospital, or MGH. This agreement was amended and restated in September 2011. Under this agreement, the Company obtained an exclusive license to develop and commercialize the patent and the core technology that underlies its CoolSculpting system. The Company conducted development from 2005 through 2009, and thereafter started commercialization of the products. The agreement will remain in full force and effect for the later of (i) the life of any patents that issue from the underlying patent applications, which are expected to expire in 2023 or (ii) one year after the last commercial sale for which a royalty is due to MGH, unless terminated in accordance with its terms and conditions. MGH may terminate the agreement upon the Company's insolvency, failure to maintain insurance, material breach of the agreement including failure to satisfy the Company's post-sales requirements, or failure to make required payments. The Company may terminate the agreement for any reason upon 90 days' advance written notice to MGH. The Company has complied with its contractual requirements to date.
	The Company is obligated to make various payments to MGH, including (i) a 7% royalty on net sales (as defined in the agreement) of CoolSculpting and (ii) milestone payments. During the year ended December 31, 2010, the Company paid MGH a $1.1 million milestone payment upon receipt of FDA clearance to market its CoolSculpting system for the selective reduction of fat. The remaining milestone payments including (i) $1 million due upon achieving cumulative net sales (as defined in the agreement) of $70 million and (ii) $6 million due upon the earlier to occur of achieving cumulative net sales (as defined in the agreement) of $200 million, or the completion of a qualifying initial public offering were made during the quarter ended December 31, 2011. As of December 31, 2011, the Company had completed all the milestones associated with the license agreement with MGH and had no milestone payments to MGH outstanding.

	All payments made to MGH prior to the FDA product approval were expensed as incurred as research and development costs. All milestone payments payable by the Company pursuant to the terms of the agreement subsequent to the date of the FDA approval were capitalized as purchased technology when paid, and are subsequently amortized into cost of revenue using the straight-line method over the estimated remaining useful life of the technology, not to exceed the term of the agreement or the life of the patent. Royalty payments are accrued as the Company recognizes revenue, and are included in cost of revenue.
	The intangible asset, net comprised the following (in thousands):


		December 31,			December 31,
		2013			2012
	Purchased technology	$	8,050		$	8,050

	Less: Accumulated amortization	(1,569		)	(869		)
	Intangible asset, net	$	6,481		$	7,181


	The amortization expense of the intangible asset was $0.7 million and $0.7 million for the years ended December 31, 2013 and 2012, respectively. The total estimated annual future amortization expense of this intangible asset as of December 31, 2013 is as follows (in thousands):


	Fiscal Year
	2014	$	701

	2015	701

	2016	701

	2017	701

	2018	701

	Thereafter	2,976

	Total	$	6,481

Notes_Payable

Notes Payable	12 Months Ended
Notes Payable	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Notes Payable	'
	Notes Payable
	On January 14, 2009, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank. The Loan Agreement provided for total borrowings of $5.0 million to be made available to the Company in three separate tranches. Tranche A, for $1.5 million, was received by the Company in January 2009. Tranche B, for $2.0 million, was received by the Company on April 30, 2009, and Tranche C, for $1.5 million, was available until September 30, 2009 and was not drawn upon. The notes payable were collateralized by substantially all the assets of the Company, excluding intellectual property. The notes carried an interest rate of 7.28% per annum. The repayment of principal, plus interest, was via monthly installments over a 36-month period for each tranche, beginning with the disbursement date of each tranche.
	On January 14, 2009, in accordance with the Loan Agreement, the Company issued a warrant to Silicon Valley Bank to purchase 47,683 shares of Series C preferred stock at $3.67 per share. The fair value of this warrant was recorded as a debt discount at issuance and has been amortized to interest expense over the term of the notes.
	During the quarter ended March 31, 2012, the remaining loan balance of $0.3 million and the final payment of 5.75% of the advanced amount, or $0.2 million, were paid in full to Silicon Valley Bank.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	Notes Receivable from a Stockholder
	In December 2007, the Company issued 445,509 shares of its common stock to an executive in exchange for full recourse promissory notes in the aggregate amount of approximately $0.2 million. The promissory notes bore interest from the date of issuance until January 1, 2010 at a rate of 4.72% per annum compounded annually and last bore interest at a rate of 4.00% per annum, and were collateralized by the related common stock and the executive’s assets. The executive separated from the Company on December 3, 2010. The promissory notes were due and payable in full (including all accrued and unpaid interest) upon nine months following the Company’s initial public offering of its common stock. These notes receivable were related to a prior exercise of stock options and were recorded as a contra stockholders’ equity account.
	In July 2012, the promissory notes were paid in full.
	Brazilian Distribution Agreement
	The Company entered into a distribution agreement with ADVANCE Medical, Inc. and its wholly owned subsidiaries, or ADVANCE, dated March 18, 2011 and amended on February 27, 2012 and September 4, 2012, appointing ADVANCE as the exclusive distributor of CoolSculpting in Brazil and Mexico. ADVANCE is required to purchase a minimum quantity of the Company’s products each calendar quarter throughout the term of the distribution agreement which expires on December 31, 2018. Venrock, a principal stockholder of the Company, owns a significant equity interest in ADVANCE Medical, Ltd., the parent company of ADVANCE. Dr. Bryan E. Roberts, who is a member of the Company's Board of Directors, is also a partner of Venrock Associates. The revenue recognized by the Company under this distribution agreement for the years ended December 31, 2013, 2012 and 2011 was $2.3 million, $2.5 million and $2.0 million, respectively. The accounts receivable balance as of December 31, 2013 and 2012, was $0.2 million and $0.1 million, respectively.

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Lease Commitments
	The Company occupies a facility in Pleasanton, a manufacturing facility in Dublin, California and a warehouse space in Livermore, California, all of which are under leases that extend through December 2014. The Company also occupies office and warehouse space in Gatwick, United Kingdom, under a lease which extends through December 2018, as well as office space in Dubai, United Arab Emirates, under a lease which extends through March 2014 and Seoul, South Korea under a lease which extends through October 2014. Rent expense for non-cancellable operating leases with scheduled rent increases is recognized on a straight-line basis over the lease term. Rent expense for the years ended December 31, 2013, 2012 and 2011 was $1.4 million, $1.2 million and $0.9 million, respectively.
	Future minimum lease payments under the non-cancellable operating leases as of December 31, 2013 are as follows (in thousands):


	Year Ending December 31,	Amount
	2014	$	1,252

	2015	30

	2016	61

	2017	61

	2018	61

	Total future minimum lease payments	$	1,465


	Purchase Commitments
	The Company had non-cancellable purchase obligations to contract manufacturers and suppliers for $6.0 million and $2.2 million at December 31, 2013 and 2012, respectively.

	Unrecognized Tax Benefits
	The table above excludes the Company's gross liability for unrecognized tax benefits which totaled $0.1 million, including estimated interest and penalties, as of December 31, 2013, and are classified in long-term income taxes payable. The Company is unable to make a reasonably reliable estimate of the timing of payments in individual years due to uncertainties in the timing of tax audits, if any, or their outcomes. Accordingly, the Company has excluded this obligation from the schedule summarizing its significant obligations to make future payments under contractual obligations as of December 31, 2013 presented above.

	Legal Matters
	From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its consolidated financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. Management reviews these estimates in each accounting period as additional information becomes known and adjusts the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements. If a loss is probable but the amount of loss cannot be reasonably estimated, the Company discloses the loss contingency and an estimate of possible loss or range of loss (unless such an estimate cannot be made). The Company does not recognize gain contingencies until they are realized. Legal costs incurred in connection with loss contingencies are expensed as incurred.
	On March 13, 2012, an alleged purchaser of the Company's publicly traded common stock, Ivan Marcano, filed a securities class action in the Superior Court of California, County of Alameda, entitled Marcano v. Nye, et al., Case No. RG12621290. The complaint alleged that the Company made false and misleading statements or omitted to state facts necessary to make the disclosures not misleading in its Form S-1, and the amendments thereto, issued in connection with the Company's initial public offering. The claims were asserted under Sections 11 and 15 of the Securities Act of 1933. On March 15, 2012, April 3, 2012, and May 24, 2012, three additional and substantially similar lawsuits were filed in the same court, some adding the Company's underwriters as defendants. All four cases were consolidated and a consolidated complaint was deemed operative. On August 24, 2012, the Company filed a demurrer to the consolidated complaint. Subsequently, Plaintiffs agreed to dismiss the Company's outside directors and its underwriters from the litigation without prejudice. On November 9, 2012, the court sustained the Company's demurrer with leave to amend. Plaintiffs filed a second amended complaint on January 14, 2013, again asserting claims under Sections 11 and 15 of the Securities Act of 1933. The second amended complaint sought compensatory damages and equitable relief on behalf of the class for an amount to be proven at trial. On February 25, 2013, the Company filed a demurrer to the second amended complaint. On May 17, 2013, the Court issued an order sustaining the demurrer without leave to amend and ordering the action dismissed. On June 7, 2013, the Court entered a judgment dismissing the action with prejudice. Plaintiffs’ time in which to appeal the judgment has lapsed and the Court’s dismissal is final.
	Indemnifications
	In the normal course of business, the Company enters into contracts that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims , and the Company believes that the estimated fair value of these indemnification obligations is minimal and has not accrued any amounts for these obligations.
	Severance and Separation Agreements
	Effective December 3, 2013, the Company's Chief Scientific Officer and Senior Vice President of Clinical entered into a separation agreement with the Company. As a result of this separation agreement, the Company incurred $0.3 million in termination benefits and $0.7 million in costs related to the modification of the employee's stock-based compensation, which were recorded during the year ended December 31, 2013. Amounts outstanding related to this separation agreement was $0.3 million as of December 31, 2013.

	Effective April 3, 2012, the Company's Vice President of North American Sales resigned from the Company. On April 18, 2012, the Company's President and CEO resigned from the positions he held with the Company. As a result of these resignations, the Company incurred $0.9 million in termination benefits and $0.7 million in costs related to the modification of the employees' stock-based compensation, which were recorded during the year ended December 31, 2012. Subsequent to these resignations, during the second quarter of 2012, the Company's management made a decision to terminate as well as accept resignations from several employees. As a result of these actions, the Company incurred approximately $0.8 million in termination benefits. Amounts outstanding related to these termination benefits were $0.4 million as of December 31, 2012. As of December 31, 2013, all of the termination benefits incurred during December 31, 2012 had been paid.

	No similar costs were incurred during the year ended December 31, 2011.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders' Equity
	Preferred Stock
	The Company's Certificate of Incorporation, as amended in October 2011, authorizes the Company to issue 50,000,000 shares of preferred stock with a par value of $0.01 per share. In connection with the IPO, all of the Company's outstanding shares of convertible preferred stock were automatically converted into 24,415,965 shares of common stock. At December 31, 2013 and 2012, the Company had no preferred stock issued or outstanding.
	Common Stock
	Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of December 31, 2013.

StockBased_Compensation_Plans

Stock-Based Compensation Plans	12 Months Ended
	Dec. 31, 2013
Share-based Compensation [Abstract]	'
Stock-Based Compensation Plans	'
	Stock-Based Compensation Plans
	2005 Stock Option Plan
	In 2005, the Company established its 2005 Stock Option Plan (the “ 2005 Plan”), which provided for the granting of stock options to employees and consultants of the Company. Options granted under the Plan were either incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs were granted only to Company employees (including officers and directors who are also employees). NSOs were granted to Company employees and consultants.

	Options under the Plan were granted for periods of up to ten years. The exercise price of an ISO and NSO should not be less than 100% and 85% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. The exercise price of an ISO and NSO granted to a 10% stockholder should not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. To date, options granted generally vested over four years at a rate of 25% upon the first anniversary of the issuance date and monthly thereafter. Cash received from employees for early exercise of unvested options was treated as a liability. Amounts so recorded were transferred into common stock and additional paid-in capital as the shares vested. The number of unvested shares and the associated liability amounts were immaterial at all reporting dates presented. As of December 31, 2013, no shares of the Company's common stock remained available for issuance under the 2005 Plan as a result of the adoption of the 2011 Equity Incentive Plan (the "2011 Plan").
	2011 Equity Incentive Plan
	In September 2011, the Company's Board of Directors approved the 2011 Plan that became effective upon the completion of the IPO.
	The 2011 Plan serves as the successor equity incentive plan to our 2005 Plan and started with 89,234 shares of common stock available for issuance plus any shares of common stock issued pursuant to the 2005 Plan or subject to awards granted under the 2005 Plan that are forfeited, repurchased, returned or otherwise become available for issuance in accordance with the terms of the 2005 Plan. In addition, this plan reserve automatically increases on January 1 and each subsequent anniversary through January 1, 2021, by an amount equal to the smaller of five percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or an amount determined by the Company's Board of Directors. The 2011 Plan provides for granting awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units, cash-based awards and other stock-based awards. Options granted under the 2011 Plan may be either ISOs or NSOs. ISOs may be granted only to the Company's employees. Any person who is not an employee of the Company on the effective date of the grant of an option may be granted only a NSO. Options under the 2011 Plan may be granted for periods of up to ten years and generally vest over a period of four years. The exercise price of an ISO and NSO shall not be less than 100% of the fair value of the shares on the date of grant. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the fair value of the underlying stock on the date of grant.
	2012 Stock Plan
	In April 2012, the Company's Board of Directors approved the 2012 Stock Plan ("2012 Plan") that became effective upon approval by the stockholders of the Company on June 15, 2012. The purpose of the 2012 Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The 2012 Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units, cash-based awards, other stock-based awards, and deferred compensation awards.
	The 2012 Plan started with 1,500,000 shares of common stock available for issuance and there are no provisions in the 2012 Plan to increase the shares available for issuance. Options granted under the 2012 Plan may be either ISOs or NSOs. ISOs may be granted only to the Company's employees. Any person who is not an employee of the Company on the effective date of the grant of an option may be granted only a NSO. Options under the 2012 Plan may be granted for periods of up to ten years and generally vest over a period of four years. The exercise price of an ISO and NSO shall not be less than 100% of the fair value of the shares on the date of grant. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the fair value of the underlying stock on the date of grant.
	Stock-based Compensation Activity
	Activity under the Company’s stock-based compensation plans is set forth below:


					Options Outstanding
		Shares			Number of			Weighted-				Weighted-Average Remaining Contractual Life (in Years)		Aggregate Intrinsic Value
		Available			Shares			Average
		for Grant						Exercise
								Price
														(in thousands)
	Balance, December 31, 2011	57,437			4,847,972			3

	Additional shares reserved	3,199,890			—			—

	Options granted	(2,989,279	)		2,989,279			5.87

	Restricted stock awards granted	(4,083	)		—			—

	Restricted stock units granted	(1,540,417	)		—			—

	Options exercised	—			(1,612,233	)		1.65

	Options canceled	2,096,684			(2,096,684	)		4.28

	Restricted stock award canceled	2,342			—			—

	Restricted stock units canceled	281,262			—			—

	Balance, December 31, 2012	1,103,836			4,128,334			$	4.96

	Additional shares reserved	1,200,000			—			—

	Options granted	(568,987	)		568,987			6.6

	Restricted stock units granted	(1,205,200	)		—			—

	Options exercised	—			(791,198	)		3.34

	Options canceled	307,738			(307,738	)		7.36

	Restricted stock award canceled	—			—			—

	Restricted stock units canceled	163,689			—			—

	Restricted stock units withheld for tax	85,661			—			—

	Balance, December 31, 2013	1,086,737			3,598,385			$	5.36			8.2		$	48,741


	Vested and expected to vest, December 31, 2013				3,440,249			$	5.34			8.18		$	46,693


Exercisable, December 31, 2013				1,795,156			$	4.94			7.86		$	25,075


The following table summarizes information about stock options outstanding as of December 31, 2013:



	Options Outstanding
Exercise Price	Stock Options Outstanding			Weighted-Average Remaining Contractual Life (in Years)			Options Exercisable
$0.55-2.42	374,146			5.7			329,604

2.83-4.30	461,190			7.9			98,163

4.60-4.62	190,000			9			40,625

5.04-5.04	1,431,092			8.6			822,879

5.06-6.34	499,199			9			221,171

6.38-9.49	370,471			8.8			186,401

9.55-10.20	149,122			7.2			65,065

11.30-11.30	54,094			4.8			20,834

12.12-12.12	19,071			8			10,414

17.33-17.33	50,000			10			—

	3,598,385						1,795,156


Restricted Stock Activity
Activity related to restricted stock units and awards is set forth below:


		Number of Units and Awards			Weighted-
					Average
					Grant Date Fair Value
Balance,	December 31, 2011	4,684			$	10.2

Restricted stock units granted		1,544,500			5.77

Restricted stock units released		(108,130	)		6.42

Restricted stock units canceled		(283,604	)		7.14

Balance,	December 31, 2012	1,157,450			$	5.38

Restricted stock units granted		1,205,200			5.57

Restricted stock units released		(292,265	)		5.35

Restricted stock units canceled		(163,689	)		4.31

Balance,	December 31, 2013	1,906,696			$	5.6

During the year ended December 31, 2013, 292,265 shares vested subject to previously granted restricted stock units. A majority of these vested restricted stock units were net share settled. During the year ended December 31, 2013, the Company withheld 85,661 shares based upon the Company's closing stock price on the vesting date to settle the employee's minimum statutory obligation for the applicable income and other employment taxes. During the year ended December 31, 2012, 108,130 shares vested subject to previously granted restricted stock units.
2011 Employee Stock Purchase Plan
In September 2011, the Company's Board of Directors approved the 2011 Employee Stock Purchase Plan (“2011 ESPP”) that became effective upon the completion of the IPO. The 2011 ESPP is designed to enable eligible employees to purchase shares of the Company's common stock at a discount. Each offering period consists of one six-month purchase period. The purchase price for shares of common stock under the 2011 ESPP is 85% of the of lesser of the fair market value of the Company's common stock on the first day of the applicable offering period or the purchase date.
There were 470,018 shares of the Company's common stock initially reserved for future purchase under our 2011 ESPP. On the first day of each year, beginning January 1, 2012 and through and including January 1, 2021, the maximum aggregate number of shares of common stock that may be issued under the 2011 ESPP will be increased by a number of shares equal to the smallest of a) one percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or b) an amount determined by the Company's Board of Directors. During 2013, the number of shares of the Company's common stock reserved for future purchase under the 2011 ESPP was increased by 150,000 shares.
The initial offering period commenced on October 19, 2011, and ended on May 31, 2012. The future offering periods will commence on or about the first trading days of December and June of each year and end on or about the last trading days of the next May and November, respectively.
During the year ended December 31, 2013, employees purchased 188,467 shares under the 2011 ESPP at a weighted average exercise price of $4.20. As of December 31, 2013, there were 298,188 shares of the Company's common stock available for future purchase under our 2011 ESPP.
Stock-Based Compensation Expense
The stock-based compensation expense related to all of our stock-based awards and employee stock purchases was allocated as follows (in thousands):


	Year Ended December 31,
	2013				2012				2011
Cost of revenue	$	248			$	131			$	54

Research and development	1,645				894				542

Sales and marketing	1,783				827				533

General and administrative	2,984				3,137				1,150

Total stock-based compensation	$	6,660			$	4,989			$	2,279

Stock-based compensation expense includes charges related to performance based stock options and restricted stock units granted to certain executives. Stock-based compensation expense related to performance based stock options and restricted stock units was $1.0 million and $0.3 million for the years ended December 31, 2013 and 2012, respectively. There were no such charges in the year ended December 31, 2011.
Additionally, stock-based compensation expense for the year ended December 31, 2013 and 2012, includes $0.7 million and $0.7 million, respectively, in modification charges incurred in connection with the severance packages to the Company's former executives. There were no such charges in the year ended December 31, 2011.
As of December 31, 2013, the total unrecognized compensation cost related to outstanding stock options, awards and employee stock purchases was $13.0 million, which will recognized using the straight-line attribution method over 2.7 years.

Stock-Based Compensation Associated with Awards to Employees
The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The valuation model for stock compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term (weighted-average period of time that the options granted are expected to be outstanding); volatility of the Company's common stock, an assumed-risk-free interest rate and the estimated forfeitures of unvested stock options. The fair value of employee stock options was estimated using the following weighted-average assumptions:



	Year Ended December 31,
	2013			2012			2011
Expected term (in years)	4.8			5.2			6

Expected volatility	51	%		61	%		59	%
Risk-free interest rate	1.02	%		0.76	%		1.05-2.65%

Expected dividend yield	0	%		0	%		0	%
Fair Value of Common Stock. The fair value of the underlying common stock was determined by the Board of Directors until the IPO when the Company's common stock started trading on the NASDAQ Global Select Market under ticker symbol ZLTQ on October 19, 2011. Consequently, after the IPO the fair value of the shares of common stock underlying the stock options is the closing price on the option grant date. Prior to the IPO, the fair value of the shares of common stock underlying the stock options was determined by the Board of Directors. Because there was no public market for the Company's common stock, the Board of Directors determined fair value of the common stock at the time of grant of the option by considering a number of objective and subjective factors including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, amongst other factors.
Expected Term. Prior to the IPO, the Company derived the expected term using the “simplified” method (the expected term is determined as the average of the time-to-vesting and the contractual life of the options), as the Company had limited historical information to develop expectations about future exercise patterns and post-vesting employment termination behavior. Subsequent to the IPO, the expected term used was based on expected term of a group of similar entities, referred to as “guideline” companies. In evaluating similarity, the Company considered factors such as industry, stage of life cycle and size.

Volatility. Prior to the IPO, because the Company was a private entity with no historical data regarding the volatility of its common stock, the expected volatility used was based on volatility of a group of similar entities, referred to as “guideline” companies. In evaluating similarity, the Company considered factors such as industry, stage of life cycle and size. Subsequent to the IPO, the Company has continued to estimate its volatility based on this group of similar entities as the Company does not have sufficient historical data regarding its specific volatility.
Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options.
Dividend Yield. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend yield of zero in the valuation model.
Forfeitures. The Company is required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.
During the years ended December 31, 2013, 2012 and 2011, the Company granted 543,987; 2,860,927 and 1,305,620 stock options, respectively, to employees with a weighted-average grant date fair value of $6.75, $3.07, and $5.65 per share, respectively. The aggregate intrinsic value of options exercised was $6.8 million, $6.0 million and $5.7 million for the years ended December 31, 2013, 2012, and 2011, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company's common stock at the date of exercise. The total fair value of shares vested was $4.9 million, $2.1 million and $0.9 million for the years ended December 31, 2013, 2012 and 2011, respectively.
During the years ended December 31, 2013, 2012 and 2011, the Company granted 1,180,200; 1,412,066 and 11,495 restricted stock units and restricted awards, respectively, to employees. The weighted-average grant date fair value as of the respective grant date of restricted stock units and restricted stock awards was $5.62, $5.70 and $10.20 for the years ended December 31, 2013, 2012 and 2011, respectively. There were no such awards granted for the year ended December 31, 2011. The fair value as of the respective vesting dates of restricted stock units and restricted stock awards was $1.4 million and $0.3 million for the year ended December 31, 2013 and December 31, 2012, respectively. The fair value as of the respective vesting dates of restricted stock units and restricted stock awards for the year ended December 31, 2011, was immaterial.
There was no capitalized stock-based compensation cost and no recognized stock-based compensation tax benefits during the years ended December 31, 2013, 2012 and 2011.

Stock-Based Compensation for Non-employees
Stock-based compensation expense related to stock-based awards to non-employees is recognized as the stock-based awards are earned, generally through the provision of services. The Company believes that the fair value of the stock-based awards is more reliably measurable than the fair value of the services received. The fair value of the granted stock-based awards is calculated at each reporting date using the Black-Scholes option pricing model. During the year ended December 31, 2013, the Company granted stock-based awards to non-employees which vest over 0.5 years. During the year ended December 31, 2012, the Company granted stock-based awards to non-employees which vest over 0.5 years. Stock-based compensation expense related to non-employee grants was $0.5 million and $0.8 million for the years ended December 31, 2013 and 2012, respectively. Stock-based compensation expense related to non-employee grants was insignificant for the year ended December 31, 2011.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2013
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Employee Benefit Plans	'
	Employee Benefit Plans

	In 2005, the Company adopted a retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all employees in the United States who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the plan may be made at the discretion of the Board of Directors. Matching 401(k) contributions expensed were $1.1 million, $0.7 million, and $0.5 million for the years ended December 31, 2013, 2012, and 2011, respectively.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes

	The domestic and foreign components of loss before provision for income taxes were as follows (in thousands):


		Year Ended December 31,
		2013				2012				2011
	Domestic	$	(19,535	)		$	(30,329	)		$	(9,051	)
	Foreign	370				327				(504		)
	Foreign	370				327				(504		)
	Loss before provision for income taxes	$	(19,165	)		$	(30,002	)		$	(9,555	)

	The provision for income taxes consisted of the following (in thousands):


		As of December 31,
		2013				2012				2011
	Current provision:
	Federal	$	—			$	—			$	—
	Federal	$	—			$	—			$	—
	State	60				37				48
	State	60				37				48
	Foreign	61				170				—
	Foreign	61				170				—
	Total current	121				207				48
	Total current	121				207				48

	Deferred provision (benefit):
	Federal	—				—				—
	Federal	—				—				—
	State	—				—				—
	State	—				—				—
	Foreign	19				(66		)		—
	Foreign	19				(66		)		—
	Total deferred	19				(66		)		—
	Total deferred	19				(66		)		—
	Total provision	$	140			$	141			$	48
	Total provision	$	140			$	141			$	48

	The following is a reconciliation of the statutory federal income tax rate to the Company's effective tax:


		Year Ended December 31,
		2013			2012			2011
	Tax at federal statutory rate	35	%		35	%		35	%
	State income taxes, net of federal benefit	2			(1	)		(1	)
	State income taxes, net of federal benefit	2			(1	)		(1	)
	Non-deductible permanent difference	(1	)		—			(3	)
	Non-deductible permanent difference	(1	)		—			(3	)
	Change in valuation allowance	(34	)		(34	)		(31	)
	Research & development credits	(2	)		1			3
	Research & development credits	(2	)		1			3
	Stock-based compensation	(1	)		(1	)		(5	)
	Other	—			—			2
	Other	—			—			2
	Provision for income taxes	(1	)%		—	%		—	%

	Tax effects of temporary differences that give rise to significant portions of the deferred tax assets are presented below (in thousands):


		December 31,
		2013				2012
	Net operating loss carryforwards	$	45,401			$	38,385
	Net operating loss carryforwards	$	45,401			$	38,385
Research & development credits	2,335				2,703
Research & development credits	2,335				2,703
Depreciation & amortization	583				312
Depreciation & amortization	583				312
Accruals & reserves	2,731				3,592
Accruals & reserves	2,731				3,592
Total deferred tax assets	51,050				44,992
Total deferred tax assets	51,050				44,992
Valuation allowance	(51,003		)		(44,926		)
Net deferred tax assets	$	47			$	66
Net deferred tax assets	$	47			$	66

As of December 31, 2013, the Company had federal and state net operating loss carryforwards of $121.3 million and $108.2 million, respectively. Unrecognized deferred tax benefits of approximately $7.9 million resulted from the exercises of employee stock awards will be accounted for as a credit to the additional paid-in capital if and when realized through a reduction in income tax payable. The federal net operating losses begin expiring in 2026 and state net operating losses begin expiring in 2015. As of December 31, 2013, the Company had research and development credit carryforwards of approximately $2.8 million and $3.0 million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal research and development credit carryforwards expire beginning 2026, and state credits can be carried forward indefinitely.

On January 2, 2013, the President signed into law The American Taxpayer Relief Act of 2012, or ATRA. Under prior law, a taxpayer was entitled to a research tax credit for qualifying amounts incurred through December 31, 2011. The ATRA extends the research credit for two years for qualified research expenditures incurred through the end of 2013. The extension of the research credit is retroactive and includes amounts incurred after 2011. The benefit of the reinstated credit did not impact the income statement in the period of enactment, which was the first quarter of 2013, as the research and development credit carryforwards are offset by a full valuation allowance.
Management believes that, based on a number of factors, which includes the Company’s historical operating performance and accumulated deficit, it is more likely than not that the U.S. deferred tax assets will not be utilized, such that a full valuation allowance has been recorded against our U.S. deferred tax assets. Valuation allowance increased by approximately $6.1 million, and $12.1 million for the years ended December 31, 2013 and 2012, respectively.
The valuation allowance for deferred tax assets consisted of the following activity for the fiscal years ended December 31, 2013, 2012 and 2011 (in thousands):


Description	Balance at Beginning of Year				Additions				Reductions				Balance at End of Year
Year ended December 31, 2011	$	29,231			$	3,605			$	—			$	32,836
Year ended December 31, 2011	$	29,231			$	3,605			$	—			$	32,836
Year ended December 31, 2012	32,836				12,090				—				44,926
Year ended December 31, 2012	32,836				12,090				—				44,926
Year ended December 31, 2013	$	44,926			$	6,077			$	—			$	51,003
Year ended December 31, 2013	$	44,926			$	6,077			$	—			$	51,003
Utilization of net operating losses and tax credit carryforwards may be limited by “ownership change” rules, as defined in Section 382 of the Internal Revenue Code. Similar rules may apply under state tax laws. The Company has assessed the application of Internal Revenue Code Section 382, during the fourth quarter of 2013, and concluded no limitation currently applies, and the Company will continue to monitor activities in the future. In the event the Company experiences any subsequent changes in ownership, the amount of net operating losses and research and development credit carryovers available in any taxable year could be limited and may expire unutilized.
During the year ended December 31, 2013, the amount of gross unrecognized tax benefits increased by $2.0 million. The total amount of unrecognized tax benefits was $2.9 million as of December 31, 2013, of which $0.1 million, if recognized, would affect the effective tax rate due to the valuation allowance that currently offsets deferred tax assets. The Company recognizes interest and penalties related to uncertain tax positions as part of the income tax provision. To date, such interest and penalties have not been material.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):


Balance as of January 1, 2011	$	678
Balance as of January 1, 2011	$	678
Additions based on tax positions related to the current year	146
	146
Balance as of December 31, 2011	824
Balance as of December 31, 2011	824
Additions based on tax positions related to the current year	78
	78
Balance as of December 31, 2012	902
Balance as of December 31, 2012	902
Additions based on tax positions related to the current year	2,023
	2,023
Balance as of December 31, 2013	$	2,925
Balance as of December 31, 2013	$	2,925

The Company files income tax returns in the U.S. federal and state jurisdictions and in the United Kingdom and all returns since inception remain open to examination.

Net_Loss_Per_Share_Of_Common_S

Net Loss Per Share Of Common Stock	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Net Loss per Share of Common Stock	'
	Net Loss per Share of Common Stock
	Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities outstanding during the period, including options, restricted stock units, stock issuable pursuant to the ESPP, warrants, and convertible preferred stock. Basic and diluted net loss per share attributable to common stockholders was the same for all periods presented as the inclusion of all potentially dilutive securities outstanding were anti-dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss are the same for each period presented.
	A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net loss per share is as follows:



		Year Ended
		December 31,
		2013				2012			2011
	Historical net loss per share:
	Numerator
	Net loss attributable to common stockholders (in thousands)	$	(19,305	)		$	(30,143	)	$	(14,702	)
	Denominator
	Weighted average shares of common stock outstanding used in computing net loss per share attributable to common stockholders - basic and diluted	36,209,051				34,776,380			7,506,282

	Basic and diluted net loss per share attributable to common stockholders	$	(0.53	)		$	(0.87	)	$	(1.96	)

	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented, because including them would have been anti-dilutive:



		Year Ended
		December 31,
		2013			2012			2011
	Options to purchase common stock	3,598,385			4,128,334			4,847,972

	Restricted stock units	1,906,696			119,507			—

	Common stock issuable pursuant to the ESPP	86,026			21,586			—

	Total	5,591,107			4,269,427			4,847,972

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Information [Abstract]	'
Supplemental Cash Flow Information	'
	Supplemental Cash Flow Information

	The supplemental cash flow information consists of the following (in thousands):



		Year Ended
		December 31,
		2013			2012			2011
	Cash paid for interest	$	—		$	2		$	69

	Cash paid for income taxes	$	188		$	47		$	—

	Non-cash investing and financing activities:
	Changes in accounts payable and accrued liabilities related to property, plant and equipment purchases	$	(33	)	$	(100	)	$	147

	Reclassification of warrant liability to additional paid-in capital upon initial public offering	$	—		$	—		$	921

	Conversion of preferred stock into common stock upon initial public offering	$	—		$	—		$	81,164

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Information	'
	Segment Information
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has a single reportable segment structure. All of the Company’s principal operations and decision-making functions are located in the United States.
	The Company’s revenue by geographic region, based on the location to where the product was shipped, is summarized as follows (in thousands):



		Year Ended
		December 31,
		2013		2012		2011
	North America	$	89,150	$	56,657	$	50,332

	International	22,476		19,537		17,812

	Total	$	111,626	$	76,194	$	68,144

	North America includes the United States and related territories as well as Canada. International is the rest of the world. Revenue for the United States was $83.7 million, $54.7 million and $47.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	The following table sets forth revenue by product expressed as dollar amounts (in thousands):



		Year Ended
		December 31,
		2013		2012		2011
	System revenue	$	61,359	$	39,145	$	46,552

	Consumable revenue	50,267		37,049		21,592

	Total	$	111,626	$	76,194	$	68,144

	Substantially all of the Company’s long-lived assets are located in the United States of America.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Selected Quarterly Financial Data (unaudited)	'
	Selected Quarterly Financial Data (unaudited)

	The following table presents selected unaudited consolidated financial data for each of the eight quarters in the two-year period ended December 31, 2013. The selected quarterly financial data should be read in conjunction with our consolidated financial statements and the related notes and "Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations". This information has been derived from our unaudited consolidated financial statements that, in our opinion, reflect all recurring adjustments necessary to fairly state this information when read in conjunction with our consolidated financial statements and the related notes appearing in the section entitled "Consolidated Financial Statements". Net loss per share-basic and diluted, for the four quarters of each fiscal year may not sum to the total for the fiscal year because of the different number of shares outstanding during each period. The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period.




		Quarter
		First			Second			Third			Fourth
		(In thousands, except share and per share data)
	Year Ended December 31, 2013
	Total revenue	$	19,982		$	26,338		$	29,465		$	35,841

	Gross profit	$	12,634		$	18,460		$	21,229		$	25,114

	Net loss	$	(7,482	)	$	(3,607	)	$	(2,811	)	$	(5,405	)
	Net loss per share, basic and diluted	$	(0.21	)	$	(0.10	)	$	(0.08	)	$	(0.15	)
	Shares used in calculation-basic and diluted	35,890,084			36,045,346			36,206,008			36,686,053


	Year Ended December 31, 2012
	Total revenue	$	17,404		$	22,265		$	17,928		$	18,597

	Gross profit	$	11,411		$	15,115		$	11,975		$	12,186

	Net loss	$	(10,345	)	$	(8,101	)	$	(5,182	)	$	(6,515	)
	Net loss per share, basic and diluted	$	(0.30	)	$	(0.24	)	$	(0.15	)	$	(0.18	)
	Shares used in calculation-basic and diluted	34,010,432			34,253,357			35,068,076			35,764,666

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. The primary estimates underlying the Company's financial statements include the value of revenue elements, product warranty, inventory valuation, allowance for doubtful accounts receivable, assumptions regarding variables used in calculating the fair value of the Company's equity awards, fair value of investments, useful lives of intangibles, income taxes and contingent liabilities. Actual results could differ from those estimates.
Significant Risks and Uncertainties	'
	Significant Risks and Uncertainties
	The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals. If the Company fails to adhere to ongoing FDA Quality System Regulation, the FDA may withdraw its market clearance or take other action. The Company relies on sole-source suppliers to manufacture some of the components used in its product. The Company's manufacturers and suppliers may encounter supply interruptions or problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA's Quality System Regulation, equipment malfunction and environmental factors, any of which could delay or impede the Company's ability to meet demand.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, marketable securities and trade receivables. Our cash equivalents and marketable securities are held in safekeeping by large, credit worthy financial institutions. The Company invests our excess cash primarily in U.S. banks, government and agency bonds, money market funds and corporate obligations. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on our deposits of cash and cash equivalents.
	The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management's assessment of the collectability of specific customer accounts and the aging of the related invoices, and represents our best estimate of probable credit losses in our existing trade accounts receivable.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Investments	'
	Investments
	The Company invests its excess cash balances primarily in certificates of deposit, commercial paper, corporate bonds, and U.S. Government agency securities. Investments with original maturities greater than 90 days that mature less than one year from the consolidated balance sheet date are classified as short-term investments. The Company classifies all of its investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of accumulated other comprehensive income (loss) in stockholders' equity. Realized gains and losses from maturities of all such securities are reported in earnings and computed using the specific identification cost method. Realized gains or losses and charges for other-than-temporary declines in value, if any, on available-for-sale securities are reported in other income (expense), net as incurred. The Company periodically evaluates these investments for other-than-temporary impairment.
Inventory	'
	Inventory
	Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or market, computed on a standard cost basis. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated.
	The useful lives of the property and equipment are as follows:



	Lab equipment, tooling, and molds	5 years
	Computer equipment	3 years
	Computer software	3 years
	Furniture and fixtures	5 years
	Vehicles	5 years
	Leasehold improvements	Shorter of lease term or estimated useful life
Capitalized Software	'
	Capitalized Software
	The Company capitalizes costs associated with customized internal-use software systems that have reached the application development stage and meet recoverability tests. Such capitalized costs mainly include external direct costs utilized in developing or obtaining the applications. Capitalization of such costs begins when the preliminary project stage is complete and ceases at the point in which the project is substantially complete and is ready for its intended purpose. The capitalized costs associated with internal-use software are depreciated on a straight-line basis over each asset's estimated useful life, which is generally three years.
Intangible Asset	'
	Intangible Asset
	The intangible asset consists of an exclusive license agreement for commercializing patents and other technology. All milestone payments subsequent to the date of the FDA approval are capitalized as purchased technology when paid, and are subsequently amortized into cost of revenue using the straight-line method over the estimated remaining useful life of the technology, not to exceed the term of the agreement or the life of the patent.
Impairment of Long-Lived Assets	'
	Impairment of Long-lived Assets
	The Company reviews property and equipment and the intangible asset for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the assets' fair value determined using the projected discounted future net cash flows arising from the asset.
Revenue Recognition	'
	Revenue Recognition
	The Company’s revenue is derived from the sales of the CoolSculpting system, consisting of a control unit and applicators, and from the sale of cycles in the form of consumable procedure packs, each of which includes consumable CoolGels and CoolLiners and a disposable computer cartridge that the Company markets as the CoolCard. Embedded software exists in the CoolCard product to permit the Company’s customers to perform a fixed number of CoolSculpting procedures, or cycles. This software is not marketed separately from the CoolSculpting system or from the CoolCard. Rather, the functionality that the software provides is part of the overall CoolCard product. The CoolSculpting system is marketed as a non-invasive aesthetic device for the reduction of fat, not for its embedded software attributes included in the CoolCard that enable its use. The Company does not provide rights to upgrades and enhancements or post-contract customer support for the embedded software. In addition, the Company does not incur significant software development costs or capitalize its software development costs. Based on this assessment, the Company considers the embedded software in the CoolCard incidental to the CoolCard product as a whole and determined that revenue recognition should not be governed by the provisions of Topic 985 of the FASB Accounting Standards Codification, or ASC. The Company earns revenue from the sale of its products to its customers and to distributors. The Company recognizes revenue when persuasive evidence of an arrangement exists, transfer of title to the customer has occurred, the sales price is fixed or determinable, and collectability is probable. Revenue is deferred in the event that any of the revenue recognition criteria is not met.

	Persuasive Evidence of an Arrangement. The Company uses contracts or customer purchase orders to determine the existence of an arrangement.

	Transfer of title. Our standard terms generally specify that title transfers upon shipment to the customer. The Company uses third party shipping documents to verify that title has transferred.

	Sales Price Fixed or Determinable. The Company assesses whether the sales price is fixed or determinable at the time of the transaction. Sales prices are documented in the executed sales contract or purchase order received prior to shipment. The Company’s standard terms do not allow for trial or evaluation periods, rights of return or refund, payments contingent upon the customer obtaining financing or other terms that could impact the customer’s obligation.

	Collectability. The Company assesses whether collection is reasonably assured based on a number of factors, including the customer’s past transaction history and credit worthiness.

	Multiple-Element Arrangements. Typically, all products sold to a customer are delivered at the same time. If a partial delivery occurs as authorized by the customer, the Company allocates revenue to the various products based on their vendor-specific objective evidence of fair value, or VSOE, if VSOE exists according to ASC 605-25 as the basis of determining the relative selling price of each element. If VSOE does not exist, the Company may use third party evidence of fair value, or TPE, to determine the relative selling price of each element. If neither VSOE nor TPE exists, the Company may use management’s best estimate of the sales price, or ESP, of each element to determine the relative selling price. The relative selling prices for control units, applicators, CoolCards and extended warranty are based on established price lists and separate, stand-alone sales of these elements. The Company establishes best estimates within a range of selling prices considering multiple factors including, but not limited to, factors such as size of transaction, pricing strategies and market conditions. The Company believes the use of the ESP allows revenue recognition in a manner consistent with the underlying economics of the transaction. The Company’s products do not require maintenance or support.
Accruals for Customer Programs	'
	Accruals for Customer Programs
	The Company records an accrued liability for cooperative marketing arrangements and customer incentive programs. The estimated cost of these programs is recorded as a reduction of revenue or as an operating expense, if the Company receives a separately identifiable benefit from the customer and can reasonably estimate the fair value of that benefit. Significant management judgment and estimates must be used to determine the cost of these programs in any accounting period.

	Cooperative Marketing Arrangements. The Company offers cooperative marketing programs to its North American customers, allowing the customer to receive partial reimbursement for qualifying advertising expenditures which promote the Company's product and brand. Customer participation, as well as reimbursement amounts, is predicated upon purchase levels of CoolCards. The objective of these arrangements is to encourage advertising and promotional events to increase sales of the Company's products. Accruals for these marketing arrangements are recorded at the time of sale, or time of commitment, based on the related program parameters, review of related advertising and historical experience.

	Customer Incentive Programs. The Company's customer incentive program consists of rebates for our North American customers based on purchase levels of CoolCards. Estimated costs of consumer rebates and similar incentives are recorded at the time the incentive is offered, based on the specific terms and conditions of the program.
Cost of Revenues	'
	Cost of Revenue
	Cost of revenue consists primarily of cost of finished and semi-finished products purchased from our third-party suppliers, labor, material, and overhead involved in our internal manufacturing processes, technology amortization and royalty fees and cost of product warranty. In the event that a revenue transaction is deferred, the corresponding cost associated with the transaction will also be deferred.
Shipping and Handling	'
	Shipping and Handling
	Shipping and handling costs charged to customers are recorded as revenue. Shipping costs are included in cost of revenue.
Research and Development	'
	Research and Development
	Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, and allocated facilities costs for employees and contractors engaged in research, clinical studies, regulatory affairs, and development. The Company expenses all research and development costs in the periods in which they are incurred.
Advertising Costs	'
	Advertising costs
	The cost of advertising and media is expensed as incurred.
Product Warranty	'
	Product Warranty

	Effective in the second quarter of 2013, the Company provides a standard limited warranty on its products of generally one year for both control units and applicators for its direct customers. Prior to this change, the Company provided a standard limited warranty on its products of generally three years for control units and one year for applicators, while for direct customers in Europe, the Company offered a one year standard warranty on control units. For indirect customers in international markets the Company provides a standard limited warranty on its products of generally three years for control units and one year for applicators.

	The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based upon historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. The Company bases product warranty costs on related freight, material, technical support labor, and overhead costs. The estimated product warranty costs are assessed by considering historical costs and applying the experienced failure rates to the outstanding warranty period for products sold. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, and average repair costs, including freight, material, technical support labor, and overhead costs, for products returned under warranty.
	The Company offers an extended warranty of up to two years on both our CoolSculpting control units and CoolSculpting applicators. The Company recognizes the revenue from the sale of an extended warranty over the extended warranty coverage period. Our revenue and related obligations from sale of extended warranties to date has not been significant.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company maintains incentive plans under which incentive and nonqualified stock options are granted primarily to employees and non-employee consultants.
	Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The fair value of stock-based awards to employees is estimated using the Black-Scholes option pricing model. The Company estimates its forfeiture rate based on an analysis of its actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate assumption based on actual forfeitures, analysis of employee turnover, and other related factors.
	Stock-based compensation expense related to stock options granted to non-employees is recognized as the stock options are earned. The awards generally vest ratably over the time period the Company expects to receive services from the non-employee. The fair values attributable to these options are amortized over the service period and the unvested portion of these options is remeasured at each vesting date.
Income Taxes	'
	Income Taxes
	The Company utilizes the asset and liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse and for operating losses and tax credit carryforwards. The Company estimates our provision for income taxes and amounts ultimately payable or recoverable in multiple tax jurisdictions around the world. Estimates involve interpretations of regulations and are inherently complex. Resolution of income tax treatments in individual jurisdictions may not be known for many years after completion of any fiscal year. The Company is required to evaluate the realizability of our deferred tax assets on an ongoing basis to determine whether there is a need for a valuation allowance with respect to such deferred tax assets. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considers all available positive and negative evidence giving greater weight to our recent cumulative losses and our ability to carryback losses against prior taxable income and, commensurate with objective verifiability, the forecast of future taxable income including the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies.
	The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement. The Company reports a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company adjusts these reserves in light of changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the provision for income taxes in the period in which such determination is made. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate, as well as the related net interest. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax provision. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheet.
	The Company files annual income tax returns in multiple taxing jurisdictions around the world. A number of years may elapse before an uncertain tax position is audited and finally resolved. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that our reserves for income taxes reflect the most likely outcome. The Company adjusts these reserves, as well as the related interest, in light of changing facts and circumstances. Settlement of any particular position could require the use of cash.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities outstanding during the period, including options, restricted stock units, stock issuable pursuant to the employee stock purchase plan, warrants, and convertible preferred stock. Basic and diluted net loss per share attributable to common stockholders was the same for all periods presented as the inclusion of all potentially dilutive securities outstanding were anti-dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss are the same for each period presented.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)

	Accumulated other comprehensive income includes foreign currency translation adjustments and unrealized gains (losses) on available-for-sale securities net of tax, the impact of which has been excluded from earnings and reflected as components of stockholders' equity.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	On February 5, 2013, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. This guidance is the culmination of the FASB's redeliberation on reporting reclassification adjustments from accumulated other comprehensive income. The Company adopted this guidance effective during the first quarter of 2013 and such adoption did not have a material impact on the Company's consolidated financial statements.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	12 Months Ended
Summary Of Significant Accounting Policies (Tables)	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Allowance for Doubtful Accounts	'
	The allowance for doubtful accounts consisted of the following activity for fiscal years ended December 31, 2013, 2012 and 2011 (in thousands):


	Description		Balance at Beginning of Year			Additions		Reductions		Balance at End of Year
	Year ended December 31, 2011		$	62		$	50	$	72	$	40
	Year ended December 31, 2011		$	62		$	50	$	72	$	40
	Year ended December 31, 2012		40			329		39		330
	Year ended December 31, 2012		40			329		39		330
	Year ended December 31, 2013		330			59		389		—
	Year ended December 31, 2013		330			59		389		—
Useful Lives of Property and Equipment	'
	The useful lives of the property and equipment are as follows:



	Lab equipment, tooling, and molds	5 years
	Computer equipment	3 years
	Computer software	3 years
	Furniture and fixtures	5 years
	Vehicles	5 years
	Leasehold improvements	Shorter of lease term or estimated useful life
	Property and equipment, net comprised the following (in thousands):


		December 31,
		2013			2012
	Lab equipment, tooling and molds	$	2,071		$	1,987
	Lab equipment, tooling and molds	$	2,071		$	1,987
	Computer software	1,562			1,243
	Computer software	1,562			1,243
	Computer equipment	801			753
	Computer equipment	801			753
	Leasehold improvements	743			636
	Leasehold improvements	743			636
	Furniture and fixtures	334			288
	Furniture and fixtures	334			288
	Vehicles	35			35
	Vehicles	35			35
	Total property and equipment	5,546			4,942
	Total property and equipment	5,546			4,942
	Less: Accumulated depreciation and amortization	(3,594		)	(2,610		)
	Construction in progress	206			4
	Construction in progress	206			4
	Property and equipment, net	$	2,158		$	2,336
	Property and equipment, net	$	2,158		$	2,336
Components of accumulated other comprehensive income	'
	Components of accumulated other comprehensive income was as follows (in thousands):


		December 31,
		2013			2012
	Cumulative translation adjustments	$	77		$	—
	Cumulative translation adjustments	$	77		$	—
	Unrealized gain on marketable securities, net of tax	10			8
	Unrealized gain on marketable securities, net of tax	10			8
	Accumulated other comprehensive income	$	87		$	8
	Accumulated other comprehensive income	$	87		$	8

Fair_Value_Of_Financial_Instru1

Fair Value Of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair value of financial assets and liabilities by level within fair value hierarchy	'
	The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):



		As of December 31, 2013
		Level 1		Level 2		Level 3		Fair Value
	Financial Assets
	Cash equivalents:
	Money market funds	$	12,796	$	—	$	—	$	12,796

	Short-term investments:
	U.S. Agency securities	—		6,772		—		6,772

	U.S. Treasury	—		1,001		—		1,001

	Corporate bonds	—		8,870		—		8,870

	Commercial paper	—		999		—		999

	Certificates of deposit	1,198		—		—		1,198

	Long-term investments:
	U.S. Agency securities	—		6,956		—		6,956

	U.S. Treasury	—		1,014		—		1,014

	Corporate bonds	—		2,795		—		2,795

	Certificates of deposit	$	677	$	—	$	—	$	677

		$	14,671	$	28,407	$	—	$	43,078




		As of December 31, 2012
		Level 1		Level 2		Level 3		Fair Value
	Financial Assets
	Cash equivalents:
	Money market funds	$	18,274	$	—	$	—	$	18,274

	Short-term investments:
	U.S. Agency securities	—		11,077		—		11,077

	Corporate bonds	—		8,417		—		8,417

	Commercial paper	—		1,998		—		1,998

	Certificates of deposit	1,071		—		—		1,071

	Long-term investments:
	U.S. Agency securities	—		7,753		—		7,753

	Corporate bonds	—		5,388		—		5,388

		$	19,345	$	34,633	$	—	$	53,978

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2013
Balance Sheet Related Disclosures [Abstract]	'
Schedule of Investments	'
	The Company's short-term and long-term investments as of December 31, 2013 are as follows (in thousands):


	Short-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	6,771		$	2		$	(1	)	$	6,772

	U.S. Treasury	1,000			1			—			1,001

	Corporate bonds	8,867			3			—			8,870

	Commercial paper	999			—			—			999

	Certificates of deposit	1,198			—			—			1,198

	Total	$	18,835		$	6		$	(1	)	$	18,840



	Long-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	6,957		$	2		$	(3	)	$	6,956

	U.S. Treasury	1,013			1			—			1,014

	Corporate bonds	2,790			5			—			2,795

	Certificates of deposit	677			—			—			677

	Total	$	11,437		$	8		$	(3	)	$	11,442


	The Company's short-term and long-term investments as of December 31, 2012, are as follows (in thousands):


	Short-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	11,071		$	6		$	—		$	11,077

	Corporate bonds	8,414			3			—			8,417

	Commercial paper	1,998			—			—			1,998

	Certificates of deposit	1,071			—			—			1,071

	Total	$	22,554		$	9		$	—		$	22,563


	Long-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	7,750		$	3		$	—		$	7,753

	Corporate bonds	5,392			1			(5		)	5,388

	Total	$	13,142		$	4		$	(5	)	$	13,141

Schedule of Contractual Maturities of Investments	'
	The contractual maturities of the Company's short-term and long-term investments as of December 31, 2013, are as follows (in thousands):


		December 31, 2013
		Amortized Cost			Fair Value
	Due in one year or less	$	18,835		$	18,840

	Due in one year to five years	11,437			11,442

		$	30,272		$	30,282

Schedule of Inventory	'
	The components of inventory consist of the following (in thousands):


		December 31,
		2013			2012
	Raw materials	$	4,520		$	8,302

	Finished goods	3,886			2,569

	Total inventory	$	8,406		$	10,871

Schedule of Property and Equipment	'
	The useful lives of the property and equipment are as follows:



	Lab equipment, tooling, and molds	5 years
	Computer equipment	3 years
	Computer software	3 years
	Furniture and fixtures	5 years
	Vehicles	5 years
	Leasehold improvements	Shorter of lease term or estimated useful life
	Property and equipment, net comprised the following (in thousands):


		December 31,
		2013			2012
	Lab equipment, tooling and molds	$	2,071		$	1,987

	Computer software	1,562			1,243

	Computer equipment	801			753

	Leasehold improvements	743			636

	Furniture and fixtures	334			288

	Vehicles	35			35

	Total property and equipment	5,546			4,942

	Less: Accumulated depreciation and amortization	(3,594		)	(2,610		)
	Construction in progress	206			4

	Property and equipment, net	$	2,158		$	2,336

Schedule of Accrued Liabilities	'
	The following table shows the components of accrued liabilities (in thousands):


		December 31,
		2013			2012
	Accrued payroll and employee related expenses	$	7,863		$	3,430

	Accrued marketing expenses	3,739			3,287

	Accrued royalty	2,458			1,343

	Sales and other taxes payable	1,787			1,177

	Accrued warranty	676			902

	Accrued legal expenses	284			415

	Other accrued liabilities	1,557			522

	Total accrued liabilities	$	18,364		$	11,076

Schedule of Product Warranty Accrual	'
	The estimated product warranty accrual was as follows (in thousands):


		December 31,
		2013			2012
	Balance at the beginning of the period	$	902		$	742

	Accruals for warranties issued	197			869

	Settlements of warranty claims	(423		)	(709		)
	Balance at the end of the period	$	676		$	902

License_Agreement_With_Massach1

License Agreement With Massachusetts General Hospital (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets	'
	The intangible asset, net comprised the following (in thousands):


		December 31,			December 31,
		2013			2012
	Purchased technology	$	8,050		$	8,050

	Less: Accumulated amortization	(1,569		)	(869		)
	Intangible asset, net	$	6,481		$	7,181

Schedule of Estimated Future Amortization Expense of Intangible Assets	'
	The total estimated annual future amortization expense of this intangible asset as of December 31, 2013 is as follows (in thousands):


	Fiscal Year
	2014	$	701

	2015	701

	2016	701

	2017	701

	2018	701

	Thereafter	2,976

	Total	$	6,481

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	Future minimum lease payments under the non-cancellable operating leases as of December 31, 2013 are as follows (in thousands):


	Year Ending December 31,	Amount
	2014	$	1,252

	2015	30

	2016	61

	2017	61

	2018	61

	Total future minimum lease payments	$	1,465

StockBased_Compensation_Plans_

Stock-Based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation [Abstract]	'
Stock Options Activity	'
	Activity under the Company’s stock-based compensation plans is set forth below:


					Options Outstanding
		Shares			Number of			Weighted-				Weighted-Average Remaining Contractual Life (in Years)	Aggregate Intrinsic Value
		Available			Shares			Average
		for Grant						Exercise
								Price
													(in thousands)
	Balance, December 31, 2011	57,437			4,847,972			3

	Additional shares reserved	3,199,890			—			—

	Options granted	(2,989,279	)		2,989,279			5.87

	Restricted stock awards granted	(4,083	)		—			—

	Restricted stock units granted	(1,540,417	)		—			—

	Options exercised	—			(1,612,233	)		1.65

	Options canceled	2,096,684			(2,096,684	)		4.28

	Restricted stock award canceled	2,342			—			—

	Restricted stock units canceled	281,262			—			—

	Balance, December 31, 2012	1,103,836			4,128,334			$	4.96

	Additional shares reserved	1,200,000			—			—

	Options granted	(568,987	)		568,987			6.6

	Restricted stock units granted	(1,205,200	)		—			—

	Options exercised	—			(791,198	)		3.34

	Options canceled	307,738			(307,738	)		7.36

	Restricted stock award canceled	—			—			—

	Restricted stock units canceled	163,689			—			—

	Restricted stock units withheld for tax	85,661			—			—

	Balance, December 31, 2013	1,086,737			3,598,385			$	5.36			8.2	$	48,741


	Vested and expected to vest, December 31, 2013				3,440,249			$	5.34			8.18	$	46,693


	Exercisable, December 31, 2013				1,795,156			$	4.94			7.86	$	25,075

Summary of Stock Options Outstanding by Exercise Price Range	'
	The following table summarizes information about stock options outstanding as of December 31, 2013:



		Options Outstanding
	Exercise Price	Stock Options Outstanding			Weighted-Average Remaining Contractual Life (in Years)			Options Exercisable
	$0.55-2.42	374,146			5.7			329,604

	2.83-4.30	461,190			7.9			98,163

	4.60-4.62	190,000			9			40,625

	5.04-5.04	1,431,092			8.6			822,879

	5.06-6.34	499,199			9			221,171

	6.38-9.49	370,471			8.8			186,401

	9.55-10.20	149,122			7.2			65,065

	11.30-11.30	54,094			4.8			20,834

	12.12-12.12	19,071			8			10,414

	17.33-17.33	50,000			10			—

		3,598,385						1,795,156

Restricted Stock Activity	'
	Activity related to restricted stock units and awards is set forth below:


			Number of Units and Awards			Weighted-
						Average
						Grant Date Fair Value
	Balance,	December 31, 2011	4,684			$	10.2

	Restricted stock units granted		1,544,500			5.77

	Restricted stock units released		(108,130	)		6.42

	Restricted stock units canceled		(283,604	)		7.14

	Balance,	December 31, 2012	1,157,450			$	5.38

	Restricted stock units granted		1,205,200			5.57

	Restricted stock units released		(292,265	)		5.35

	Restricted stock units canceled		(163,689	)		4.31

	Balance,	December 31, 2013	1,906,696			$	5.6

Stock-Based Compensation Expense	'
	The stock-based compensation expense related to all of our stock-based awards and employee stock purchases was allocated as follows (in thousands):


		Year Ended December 31,
		2013				2012				2011
	Cost of revenue	$	248			$	131			$	54

	Research and development	1,645				894				542

	Sales and marketing	1,783				827				533

	General and administrative	2,984				3,137				1,150

	Total stock-based compensation	$	6,660			$	4,989			$	2,279

Summary of Fair Value of Employee Stock Option Assumptions	'
	The fair value of employee stock options was estimated using the following weighted-average assumptions:



		Year Ended December 31,
		2013			2012			2011
	Expected term (in years)	4.8			5.2			6

	Expected volatility	51	%		61	%		59	%
	Risk-free interest rate	1.02	%		0.76	%		1.05-2.65%

	Expected dividend yield	0	%		0	%		0	%

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Domestic and Foreign Loss before Provision for Income Taxes	'
	The domestic and foreign components of loss before provision for income taxes were as follows (in thousands):


		Year Ended December 31,
		2013				2012				2011
	Domestic	$	(19,535	)		$	(30,329	)		$	(9,051	)
	Foreign	370				327				(504		)
	Foreign	370				327				(504		)
	Loss before provision for income taxes	$	(19,165	)		$	(30,002	)		$	(9,555	)
Schedule of Components of Income Tax Provision	'
	The provision for income taxes consisted of the following (in thousands):


		As of December 31,
		2013				2012				2011
	Current provision:
	Federal	$	—			$	—			$	—
	Federal	$	—			$	—			$	—
	State	60				37				48
	State	60				37				48
	Foreign	61				170				—
	Foreign	61				170				—
	Total current	121				207				48
	Total current	121				207				48

	Deferred provision (benefit):
	Federal	—				—				—
	Federal	—				—				—
	State	—				—				—
	State	—				—				—
	Foreign	19				(66		)		—
	Foreign	19				(66		)		—
	Total deferred	19				(66		)		—
	Total deferred	19				(66		)		—
	Total provision	$	140			$	141			$	48
	Total provision	$	140			$	141			$	48
Schedule of Effective Income Tax Rate Reconciliation	'
	The following is a reconciliation of the statutory federal income tax rate to the Company's effective tax:


		Year Ended December 31,
		2013			2012			2011
	Tax at federal statutory rate	35	%		35	%		35	%
	State income taxes, net of federal benefit	2			(1	)		(1	)
	State income taxes, net of federal benefit	2			(1	)		(1	)
	Non-deductible permanent difference	(1	)		—			(3	)
	Non-deductible permanent difference	(1	)		—			(3	)
	Change in valuation allowance	(34	)		(34	)		(31	)
	Research & development credits	(2	)		1			3
	Research & development credits	(2	)		1			3
	Stock-based compensation	(1	)		(1	)		(5	)
	Other	—			—			2
	Other	—			—			2
	Provision for income taxes	(1	)%		—	%		—	%
Schedule of Deferred Tax Assets	'
	Tax effects of temporary differences that give rise to significant portions of the deferred tax assets are presented below (in thousands):


		December 31,
		2013				2012
	Net operating loss carryforwards	$	45,401			$	38,385
	Net operating loss carryforwards	$	45,401			$	38,385
	Research & development credits	2,335				2,703
	Research & development credits	2,335				2,703
	Depreciation & amortization	583				312
	Depreciation & amortization	583				312
	Accruals & reserves	2,731				3,592
	Accruals & reserves	2,731				3,592
	Total deferred tax assets	51,050				44,992
	Total deferred tax assets	51,050				44,992
	Valuation allowance	(51,003		)		(44,926		)
	Net deferred tax assets	$	47			$	66
	Net deferred tax assets	$	47			$	66
Summary of Valuation Allowance	'
	The valuation allowance for deferred tax assets consisted of the following activity for the fiscal years ended December 31, 2013, 2012 and 2011 (in thousands):


	Description	Balance at Beginning of Year				Additions				Reductions			Balance at End of Year
	Year ended December 31, 2011	$	29,231			$	3,605			$	—		$	32,836
	Year ended December 31, 2011	$	29,231			$	3,605			$	—		$	32,836
	Year ended December 31, 2012	32,836				12,090				—			44,926
	Year ended December 31, 2012	32,836				12,090				—			44,926
	Year ended December 31, 2013	$	44,926			$	6,077			$	—		$	51,003
	Year ended December 31, 2013	$	44,926			$	6,077			$	—		$	51,003
Summary of Unrecognized Tax Benefits	'
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):


	Balance as of January 1, 2011	$	678
	Balance as of January 1, 2011	$	678
	Additions based on tax positions related to the current year	146
		146
	Balance as of December 31, 2011	824
	Balance as of December 31, 2011	824
	Additions based on tax positions related to the current year	78
		78
	Balance as of December 31, 2012	902
	Balance as of December 31, 2012	902
	Additions based on tax positions related to the current year	2,023
		2,023
	Balance as of December 31, 2013	$	2,925
	Balance as of December 31, 2013	$	2,925

Net_Loss_Per_Share_Of_Common_S1

Net Loss Per Share Of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net loss per share is as follows:



		Year Ended
		December 31,
		2013				2012			2011
	Historical net loss per share:
	Numerator
	Net loss attributable to common stockholders (in thousands)	$	(19,305	)		$	(30,143	)	$	(14,702	)
	Denominator
	Weighted average shares of common stock outstanding used in computing net loss per share attributable to common stockholders - basic and diluted	36,209,051				34,776,380			7,506,282

	Basic and diluted net loss per share attributable to common stockholders	$	(0.53	)		$	(0.87	)	$	(1.96	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented, because including them would have been anti-dilutive:



		Year Ended
		December 31,
		2013			2012			2011
	Options to purchase common stock	3,598,385			4,128,334			4,847,972

	Restricted stock units	1,906,696			119,507			—

	Common stock issuable pursuant to the ESPP	86,026			21,586			—

	Total	5,591,107			4,269,427			4,847,972

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Information [Abstract]	'
Supplemental Cash Flow Information	'
	The supplemental cash flow information consists of the following (in thousands):



		Year Ended
		December 31,
		2013			2012			2011
	Cash paid for interest	$	—		$	2		$	69

	Cash paid for income taxes	$	188		$	47		$	—

	Non-cash investing and financing activities:
	Changes in accounts payable and accrued liabilities related to property, plant and equipment purchases	$	(33	)	$	(100	)	$	147

	Reclassification of warrant liability to additional paid-in capital upon initial public offering	$	—		$	—		$	921

	Conversion of preferred stock into common stock upon initial public offering	$	—		$	—		$	81,164

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Revenue By Geographic Region	'
	The Company’s revenue by geographic region, based on the location to where the product was shipped, is summarized as follows (in thousands):



		Year Ended
		December 31,
		2013		2012		2011
	North America	$	89,150	$	56,657	$	50,332

	International	22,476		19,537		17,812

	Total	$	111,626	$	76,194	$	68,144

Revenue By Product	'
	The following table sets forth revenue by product expressed as dollar amounts (in thousands):



		Year Ended
		December 31,
		2013		2012		2011
	System revenue	$	61,359	$	39,145	$	46,552

	Consumable revenue	50,267		37,049		21,592

	Total	$	111,626	$	76,194	$	68,144

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information	'
	The following table presents selected unaudited consolidated financial data for each of the eight quarters in the two-year period ended December 31, 2013. The selected quarterly financial data should be read in conjunction with our consolidated financial statements and the related notes and "Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations". This information has been derived from our unaudited consolidated financial statements that, in our opinion, reflect all recurring adjustments necessary to fairly state this information when read in conjunction with our consolidated financial statements and the related notes appearing in the section entitled "Consolidated Financial Statements". Net loss per share-basic and diluted, for the four quarters of each fiscal year may not sum to the total for the fiscal year because of the different number of shares outstanding during each period. The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period.




		Quarter
		First			Second			Third			Fourth
		(In thousands, except share and per share data)
	Year Ended December 31, 2013
	Total revenue	$	19,982		$	26,338		$	29,465		$	35,841

	Gross profit	$	12,634		$	18,460		$	21,229		$	25,114

	Net loss	$	(7,482	)	$	(3,607	)	$	(2,811	)	$	(5,405	)
	Net loss per share, basic and diluted	$	(0.21	)	$	(0.10	)	$	(0.08	)	$	(0.15	)
	Shares used in calculation-basic and diluted	35,890,084			36,045,346			36,206,008			36,686,053


	Year Ended December 31, 2012
	Total revenue	$	17,404		$	22,265		$	17,928		$	18,597

	Gross profit	$	11,411		$	15,115		$	11,975		$	12,186

	Net loss	$	(10,345	)	$	(8,101	)	$	(5,182	)	$	(6,515	)
	Net loss per share, basic and diluted	$	(0.30	)	$	(0.24	)	$	(0.15	)	$	(0.18	)
	Shares used in calculation-basic and diluted	34,010,432			34,253,357			35,068,076			35,764,666

The_Company_And_Basis_Of_Prese1

The Company And Basis Of Presentation (Details) (USD $)	12 Months Ended				0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 13, 2011	Oct. 24, 2011	Oct. 24, 2011	Oct. 24, 2011	Oct. 24, 2011
					IPO [Member]	Common Stock [Member]	Parent Company [Member]	Existing Stockholders [Member]
						IPO [Member]	IPO [Member]	IPO [Member]
Equity [Line Items]	'	'	'	'	'	'	'	'
Stockholders' equity note, reverse stock split, conversion ratio (Shares)	'	'	'	3.670069	'	'	'	'
Common stock, par value (per share)	$0.00	$0.00	'	$0.00	'	'	'	'
Stock issued during period, (Shares)	'	'	'	'	8,050,000	'	7,743,000	307,000
Share price (per share)	'	'	'	'	$13	'	'	'
Net proceeds from issuance initial public offering (USD)	$0	$0	$90,682	'	$90,700	'	'	'
Stock issued during period, shares, conversion of convertible securities (Shares)	'	'	'	'	'	24,415,965	'	'

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Restricted cash	$331,000	$469,000	'
Advertising expense	$8,900,000	$12,000,000	$1,900,000

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies - Concentration Of Credit Risk (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts Receivable [Roll Forward]	'	'	'
Balance at Beginning of Year	$330	$40	$62
Additions	59	329	50
Reductions	389	39	72
Balance at End of Year	$0	$330	$40

Summary_Of_Significant_Account5

Summary Of Significant Accounting Policies - Property Plant And Equipment (Details)	12 Months Ended
	Dec. 31, 2013
Lab Equipment, Tooling, and Molds [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Useful Life	'5 years
Computer Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Useful Life	'3 years
Computer Software [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Useful Life	'3 years
Furniture and Fixtures [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Useful Life	'5 years
Vehicles [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Useful Life	'5 years
Capitalized Software [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Useful Life	'3 years

Summary_Of_Significant_Account6

Summary Of Significant Accounting Policies - Warranty (Details)	3 Months Ended		12 Months Ended		9 Months Ended		3 Months Ended	12 Months Ended
	Mar. 31, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	Control Units [Member]	Applicators [Member]	Maximum [Member]	Maximum [Member]	Direct Customer [Member]	Direct Customer [Member]	Europe [Member]	International [Member]	International [Member]
			Control Units [Member]	Applicators [Member]	Control Units [Member]	Applicators [Member]	Direct Customer [Member]	Indirect Customer [Member]	Indirect Customer [Member]
							Control Units [Member]	Control Units [Member]	Applicators [Member]
Product Liability Contingency [Line Items]	'	'	'	'	'	'	'	'	'
Product Warranty Accrual, Term	'3 years	'1 year	'	'	'1 year	'1 year	'1 year	'3 years	'1 year
Product Extended Warranty Accrual, Term	'	'	'2 years	'2 years	'	'	'	'	'

Recovered_Sheet1

Summary of Significant Accounting Policies - Comprehensive Income (Loss) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'
Cumulative translation adjustments	$77	$0
Unrealized gain on marketable securities, net of tax	10	8
Accumulated other comprehensive income	$87	$8

Fair_Value_Of_Financial_Instru2

Fair Value Of Financial Instruments (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	$30,282	'
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, fair value disclosure	14,671	19,345
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, fair value disclosure	28,407	34,633
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, fair value disclosure	0	0
Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, fair value disclosure	43,078	53,978
Money Market Funds [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents, fair value disclosure	12,796	18,274
Money Market Funds [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents, fair value disclosure	0	0
Money Market Funds [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents, fair value disclosure	0	0
Money Market Funds [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents, fair value disclosure	12,796	18,274
Short-term Investments [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	18,840	22,563
Short-term Investments [Member] \| U.S. Agency Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	6,772	11,077
Short-term Investments [Member] \| U.S. Agency Securities [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Short-term Investments [Member] \| U.S. Agency Securities [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	6,772	11,077
Short-term Investments [Member] \| U.S. Agency Securities [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Short-term Investments [Member] \| U.S. Agency Securities [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	6,772	11,077
Short-term Investments [Member] \| U.S. Treasury [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,001	'
Short-term Investments [Member] \| U.S. Treasury [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	'
Short-term Investments [Member] \| U.S. Treasury [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,001	'
Short-term Investments [Member] \| U.S. Treasury [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	'
Short-term Investments [Member] \| U.S. Treasury [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,001	'
Short-term Investments [Member] \| Corporate Bonds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	8,870	8,417
Short-term Investments [Member] \| Corporate Bonds [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Short-term Investments [Member] \| Corporate Bonds [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	8,870	8,417
Short-term Investments [Member] \| Corporate Bonds [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Short-term Investments [Member] \| Corporate Bonds [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	8,870	8,417
Short-term Investments [Member] \| Commercial Paper [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Short-term Investments [Member] \| Commercial Paper [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	999	1,998
Short-term Investments [Member] \| Commercial Paper [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Short-term Investments [Member] \| Commercial Paper [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	999	1,998
Short-term Investments [Member] \| Certificates of Deposit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,198	1,071
Short-term Investments [Member] \| Certificates of Deposit [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,198	1,071
Short-term Investments [Member] \| Certificates of Deposit [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Short-term Investments [Member] \| Certificates of Deposit [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Short-term Investments [Member] \| Certificates of Deposit [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,198	1,071
Long-term Investments [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	11,442	13,141
Long-term Investments [Member] \| U.S. Agency Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	6,956	7,753
Long-term Investments [Member] \| U.S. Agency Securities [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Long-term Investments [Member] \| U.S. Agency Securities [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	6,956	7,753
Long-term Investments [Member] \| U.S. Agency Securities [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Long-term Investments [Member] \| U.S. Agency Securities [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	6,956	7,753
Long-term Investments [Member] \| U.S. Treasury [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,014	'
Long-term Investments [Member] \| U.S. Treasury [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	'
Long-term Investments [Member] \| U.S. Treasury [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,014	'
Long-term Investments [Member] \| U.S. Treasury [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	'
Long-term Investments [Member] \| U.S. Treasury [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	1,014	'
Long-term Investments [Member] \| Corporate Bonds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	2,795	5,388
Long-term Investments [Member] \| Corporate Bonds [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Long-term Investments [Member] \| Corporate Bonds [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	2,795	5,388
Long-term Investments [Member] \| Corporate Bonds [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	0
Long-term Investments [Member] \| Corporate Bonds [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	2,795	5,388
Long-term Investments [Member] \| Certificates of Deposit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	677	'
Long-term Investments [Member] \| Certificates of Deposit [Member] \| Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	677	'
Long-term Investments [Member] \| Certificates of Deposit [Member] \| Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	'
Long-term Investments [Member] \| Certificates of Deposit [Member] \| Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	0	'
Long-term Investments [Member] \| Certificates of Deposit [Member] \| Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale, fair value sale securities, fair value disclosure	$677	'

Balance_Sheet_Components_Inves

Balance Sheet Components - Investments (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	$30,272	'
Fair value	30,282	'
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized Cost, Due in one year or less	18,835	'
Amortized Cost, Due in one year to five years	11,437	'
Amortized cost	30,272	'
Fair Value, Due in one year or less	18,840	'
Fair Value, Due in one year to five years	11,442	'
Fair value	30,282	'
Short-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	18,835	22,554
Gross unrealized gains	6	9
Gross unrealized losses	-1	0
Fair value	18,840	22,563
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	18,835	22,554
Fair value	18,840	22,563
Long-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	11,437	13,142
Gross unrealized gains	8	4
Gross unrealized losses	-3	-5
Fair value	11,442	13,141
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	11,437	13,142
Fair value	11,442	13,141
U.S. Agency Securities [Member] \| Short-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	6,771	11,071
Gross unrealized gains	2	6
Gross unrealized losses	-1	0
Fair value	6,772	11,077
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	6,771	11,071
Fair value	6,772	11,077
U.S. Agency Securities [Member] \| Long-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	6,957	7,750
Gross unrealized gains	2	3
Gross unrealized losses	-3	0
Fair value	6,956	7,753
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	6,957	7,750
Fair value	6,956	7,753
U.S. Treasury [Member] \| Short-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	1,000	'
Gross unrealized gains	1	'
Gross unrealized losses	0	'
Fair value	1,001	'
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	1,000	'
Fair value	1,001	'
U.S. Treasury [Member] \| Long-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	1,013	'
Gross unrealized gains	1	'
Gross unrealized losses	0	'
Fair value	1,014	'
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	1,013	'
Fair value	1,014	'
Corporate Bonds [Member] \| Short-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	8,867	8,414
Gross unrealized gains	3	3
Gross unrealized losses	0	0
Fair value	8,870	8,417
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	8,867	8,414
Fair value	8,870	8,417
Corporate Bonds [Member] \| Long-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	2,790	5,392
Gross unrealized gains	5	1
Gross unrealized losses	0	-5
Fair value	2,795	5,388
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	2,790	5,392
Fair value	2,795	5,388
Commercial Paper [Member] \| Short-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	999	1,998
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair value	999	1,998
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	999	1,998
Fair value	999	1,998
Certificates of Deposit [Member] \| Short-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	1,198	1,071
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair value	1,198	1,071
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	1,198	1,071
Fair value	1,198	1,071
Certificates of Deposit [Member] \| Long-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	677	'
Gross unrealized gains	0	'
Gross unrealized losses	0	'
Fair value	677	'
Available-for-sale Securities, Debt Maturities [Abstract]	'	'
Amortized cost	677	'
Fair value	$677	'

Balance_Sheet_Components_Inven

Balance Sheet Components - Inventory (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventory, Net [Abstract]	'	'
Raw materials	$4,520	$8,302
Finished goods	3,886	2,569
Total inventory	$8,406	$10,871

Balance_Sheet_Components_Prope

Balance Sheet Components - Property and Equipment, Net (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$5,546,000	$4,942,000	'
Less: Accumulated depreciation and amortization	-3,594,000	-2,610,000	'
Property and equipment, net	2,158,000	2,336,000	'
Depreciation	1,000,000	900,000	700,000
Lab Equipment, Tooling and Molds [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	2,071,000	1,987,000	'
Computer Software [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	1,562,000	1,243,000	'
Computer Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	801,000	753,000	'
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	743,000	636,000	'
Furniture and Fixtures [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	334,000	288,000	'
Vehicles [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	35,000	35,000	'
Construction in Progress [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$206,000	$4,000	'

Balance_Sheet_Components_Accru

Balance Sheet Components - Accrued Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Balance Sheet Related Disclosures [Abstract]	'	'
Accrued payroll and employee related expenses	$7,863	$3,430
Accrued marketing expenses	3,739	3,287
Accrued royalty	2,458	1,343
Sales and other taxes payable	1,787	1,177
Accrual warranty	676	902
Accrued legal expense	284	415
Other accrued liabilities	1,557	522
Total accrued liabilities	$18,364	$11,076

Balance_Sheet_Components_Warra

Balance Sheet Components - Warranty (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Movement in Standard Product Warranty Accrual [Roll Forward]	'	'
Balance at the beginning of the period	$902	$742
Accruals for warranties issued	197	869
Settlements of warranty claims	-423	-709
Balance at the end of the period	$676	$902

License_Agreement_With_Massach2

License Agreement With Massachusetts General Hospital (Details) (USD $)	1 Months Ended	12 Months Ended
	30-May-05	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Period that agreement remains in full force after last commercial sale with royalty due	'1 year	'	'	'	'
Period to terminate contract with written notice	'90 days	'	'	'	'
Royalty expense, percent of net sales	'	7.00%	'	'	'
Payments to Acquire Intangible Assets	'	$0	$0	$7,000,000	$1,100,000
Amortization of intangible assets	'	700,000	700,000	'	'
License Agreement Milestone 1 [Member]	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Payments to Acquire Intangible Assets	'	'	'	1,000,000	'
Cumulative net sales required for milestone payment	'	'	'	70,000,000	'
License Agreement Milestone 2 [Member]	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Payments to Acquire Intangible Assets	'	'	'	6,000,000	'
Cumulative net sales required for milestone payment	'	'	'	$200,000,000	'

License_Agreement_With_Massach3

License Agreement With Massachusetts General Hospital - Intangible Asset, Net Comprises (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Purchased technology	$8,050	$8,050
Less: accumulated amortization	-1,569	-869
Intangible asset, net	$6,481	$7,181

License_Agreement_With_Massach4

License Agreement With Massachusetts General Hospital - Estimated Annual Future Amortization Expense (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
2014	$701	'
2015	701	'
2016	701	'
2017	701	'
2018	701	'
Thereafter	2,976	'
Intangible asset, net	$6,481	$7,181

Notes_Payable_Details

Notes Payable (Details) (USD $)	12 Months Ended			3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2012	Jan. 14, 2009	Jan. 14, 2009	Jan. 31, 2009	Apr. 30, 2009	Sep. 30, 2009	Jan. 14, 2009
				Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Series C Convertible Preferred Stock [Member]
						Loan Agreement [Member]	Tranche A [Member]	Tranche B [Member]	Tranche C [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Debt instrument, maximum borrowing amount	'	'	'	'	'	$5,000,000	'	'	'	'
Debt instrument, face amount	'	'	'	'	'	'	1,500,000	2,000,000	1,500,000	'
Debt instrument, interest rate, stated percentage	'	'	'	'	7.28%	'	'	'	'	'
Debt instrument, monthly installments	'36 months	'	'	'	'	'	'	'	'	'
Preferred stock warrants, number of securities called by warrants (shares)	'	'	'	'	'	'	'	'	'	47,683
Preferred stock warrants, exercise price (per share)	'	'	'	'	'	'	'	'	'	3.67
Repayments of notes payable	0	310,000	1,335,000	300,000	'	'	'	'	'	'
Final payment, balloon payment interest rate	'	'	'	5.75%	'	'	'	'	'	'
Final payment, balloon payment amount	'	'	'	$200,000	'	'	'	'	'	'

Related_Party_Transactions_Not

Related Party Transactions - Note Receivable From a Stockholder (Details) (USD $)	0 Months Ended	1 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 02, 2010	Dec. 31, 2007
Related Party Transaction [Line Items]	'	'
Stockholders' equity note, subscriptions receivable	'	0.2
Executive Officer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Related party transaction, rate	4.00%	4.72%
Common Stock [Member] \| Executive Officer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Stock issued during period, shares, new issues (shares)	'	445,509

Related_Party_Transactions_Bra

Related Party Transactions - Brazilian Distribution Agreement (Details) (Distributor [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Distributor [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Revenue from related parties	$2.30	$2.50	$2
Accounts receivable, related parties	$0.20	$0.10	'

Commitments_And_Contingencies_1

Commitments And Contingencies - Lease Commitments (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Rent expense	$1,400,000	$1,200,000	$900,000
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'	'
2014	1,252,000	'	'
2015	30,000	'	'
2016	61,000	'	'
2017	61,000	'	'
2018	61,000	'	'
Total future minimum lease payments	$1,465,000	'	'

Commitments_And_Contingencies_2

Commitments And Contingencies - Purchase Commitments (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]	'	'
Purchase obligation	$6	$2.20

Recovered_Sheet2

Commitments and Contingencies - Unrecognized Tax Benefits (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Unrecognized tax benefits	$0.10

Commitments_And_Contingencies_3

Commitments And Contingencies - Legal Matters (Details)	0 Months Ended				12 Months Ended
	24-May-12	Apr. 03, 2012	Mar. 15, 2012	Mar. 13, 2012	Dec. 31, 2012
	Cases	Cases	Cases	Cases	Cases
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Number of lawsuits	1	1	1	1	4

Commitments_And_Contingencies_4

Commitments And Contingencies - Severance (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2012
Loss Contingencies [Line Items]	'	'	'
Termination benefits	'	'	$0.80
Stock-based compensation expense due to modification	0.7	0.7	'
Termination benefits liability	0.3	0.4	'
Management [Member]	'	'	'
Loss Contingencies [Line Items]	'	'	'
Termination benefits	0.3	0.9	'
Stock-based compensation expense due to modification	$0.70	$0.70	'

Stockholders_Equity_Preferred_

Stockholders' Equity - Preferred Stock (Details) (USD $)	1 Months Ended
Stockholders' Equity - Preferred Stock (Details) (USD $)	Oct. 31, 2011	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]	'	'	'
Preferred stock, shares authorized	50,000,000	50,000,000	50,000,000
Preferred stock, par value (dollars per share)	$0.01	$0.01	$0.01
Conversion of preferred stock into common stock upon initial public offering, shares	24,415,965	'	'
Preferred stock, shares issued	'	0	0
Preferred stock, shares outstanding	'	0	0

Stockholders_Equity_Common_Sto

Stockholders' Equity - Common Stock (Details) (Common Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2013
	vote
Common Stock [Member]	'
Class of Stock [Line Items]	'
Number of votes per share	1
Dividends declared	$0
Dividends paid	$0

StockBased_Compensation_Plans_1

Stock-Based Compensation Plans (Details) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Sep. 30, 2011

Dec. 31, 2013

Apr. 30, 2012

Dec. 31, 2013

Sep. 30, 2011

Dec. 31, 2013

2005 Equity Incentive Plan [Member]

2011 Equity Incentive Plan [Member]

2012 Stock Plan [Member]

2011 Employee Stock Purchase Plan [Member]

10% Stockholder [Member]

ISO [Member]

NSO [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

2005 Equity Incentive Plan [Member]

2011 Equity Incentive Plan [Member]

2012 Stock Plan [Member]

2005 Equity Incentive Plan [Member]

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of stock purchase price

100.00%

85.00%

110.00%

100.00%

85.00%

Vesting period

'4 years

Vesting rate

25.00%

Common stock available for issuance

89,234

1,500,000

470,018

Increase in shares at each annual anniversary, percent

5.00%

1.00%

Period options may be granted

'10 years

Additional shares reserved for future purchase under plan

1,200,000

3,199,890

150,000

Shares purchased

188,467

Weighted average exercise price

$4.20

Shares reserved for future issuance

1,086,737

1,103,836

57,437

298,188

StockBased_Compensation_Plans_2

Stock-Based Compensation Plans - Stock Options Plan Activity (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]	'	'
Balance at beginning of period, Shares	1,103,836	57,437
Additional shares reserved, Shares	1,200,000	3,199,890
Options granted, Shares	-568,987	-2,989,279
Options canceled, Shares	307,738	2,096,684
Balance at end of period, Shares	1,086,737	1,103,836
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Balance at beginning of period, Shares	4,128,334	4,847,972
Options granted, Shares	568,987	2,989,279
Options exercised, Shares	-791,198	-1,612,233
Options canceled, Shares	-307,738	-2,096,684
Balance at end of period, Shares	3,598,385	4,128,334
Vested and expected to vest, end of period, Shares	3,440,249	'
Exercisable, end of period, Shares	1,795,156	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'
Balance at beginning of period, Weighted-Average Exercise Price, Per Share	$4.96	$3
Options granted, Weighted-Average Exercise Price, Per Share	$6.60	$5.87
Options exercised, Weighted-Average Exercise Price, Per Share	$3.34	$1.65
Options canceled, Weighted-Average Exercise Price, Per Share	$7.36	$4.28
Balance at ending of period, Weighted-Average Exercise Price, Per Share	$5.36	$4.96
Vested and expected to vest, end of period, Weighted-Average Exercise Price, Per Share	$5.34	'
Exercisable, end of period, Weighted-Average Exercise Price, Per Share	$4.94	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'
Balance at end of period, Weighted-Average Remaining Contractual Life	'8 years 2 months 12 days	'
Balance at end of period, Aggregate Intrinsic Value	$48,741	'
Vested and expected to vest, end of period, Weighted-Average Remaining Contractual Life	'8 years 2 months 5 days	'
Vested and expected to vest, end of period, Aggregate Intrinsic Value	46,693	'
Exercisable, end of period, Weighted-Average Remaining Contractual Life	'7 years 10 months 10 days	'
Exercisable, end of period, Aggregate Intrinsic Value	$25,075	'
Restricted stock awards [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]	'	'
Restricted stock awards/units granted, Shares	'	-4,083
Restricted stock awards/units canceled, shares	0	2,342
Restricted stock units [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]	'	'
Restricted stock awards/units granted, Shares	-1,205,200	-1,540,417
Restricted stock awards/units canceled, shares	163,689	281,262
Restricted stock units withheld for tax, shares	85,661	'

StockBased_Compensation_Plans_3

Stock-Based Compensation Plans - Stock Options Outstanding (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	3,598,385
Options exercisable	1,795,156
$0.55-2.42 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	374,146
Weighted-average remaining contractual life	'5 years 8 months 12 days
Options exercisable	329,604
Exercise price, lower limit	$0.55
Exercise price, upper limit	$2.42
2.83-4.30 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	461,190
Weighted-average remaining contractual life	'7 years 10 months 24 days
Options exercisable	98,163
Exercise price, lower limit	$2.83
Exercise price, upper limit	$4.30
4.60-4.62 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	190,000
Weighted-average remaining contractual life	'9 years
Options exercisable	40,625
Exercise price, lower limit	$4.60
Exercise price, upper limit	$4.62
5.04-5.04 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	1,431,092
Weighted-average remaining contractual life	'8 years 7 months 6 days
Options exercisable	822,879
Exercise price, lower limit	$5.04
Exercise price, upper limit	$5.04
5.06-6.34 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	499,199
Weighted-average remaining contractual life	'9 years
Options exercisable	221,171
Exercise price, lower limit	$5.06
Exercise price, upper limit	$6.34
6.38-9.49 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	370,471
Weighted-average remaining contractual life	'8 years 9 months 18 days
Options exercisable	186,401
Exercise price, lower limit	$6.38
Exercise price, upper limit	$9.49
9.55-10.20 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	149,122
Weighted-average remaining contractual life	'7 years 2 months 12 days
Options exercisable	65,065
Exercise price, lower limit	$9.55
Exercise price, upper limit	$10.20
11.30-11.30 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	54,094
Weighted-average remaining contractual life	'4 years 9 months 18 days
Options exercisable	20,834
Exercise price, lower limit	$11.30
Exercise price, upper limit	$11.30
12.12-12.12 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	19,071
Weighted-average remaining contractual life	'8 years
Options exercisable	10,414
Exercise price, lower limit	$12.12
Exercise price, upper limit	$12.12
17.33-17.33 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock options outstanding	50,000
Weighted-average remaining contractual life	'10 years
Options exercisable	0
Exercise price, lower limit	$17.33
Exercise price, upper limit	$17.33

StockBased_Compensation_Plans_4

Stock-Based Compensation Plans Stock-Based Compensation Plans - Restricted Stock Activity (Details) (Restriced Stock Units and Awards [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Restriced Stock Units and Awards [Member]	'	'
Number of Units and Awards	'	'
Beginning balance (shares)	1,157,450	4,684
Restricted stock units granted (shares)	1,205,200	1,544,500
Restricted stock units released (shares)	-292,265	-108,130
Restricted stock units canceled (shares)	-163,689	-283,604
Ending balance (shares)	1,906,696	1,157,450
Weighted-Average Grant Date Fair Value	'	'
Beginning Balance (weighted average exercise price) (per share)	$5.38	$10.20
Restricted stock units granted (weighted average exercise price) (per share)	$5.57	$5.77
Restricted stock units released (weighted average exercise price) (per share)	$5.35	$6.42
Restricted stock units canceled (weighted average exercise price) (per share)	$4.31	$7.14
Ending Balance (weighted average exercise price) (per share)	$5.60	$5.38

StockBased_Compensation_Plans_5

Stock-Based Compensation Plans - Stock-Based Compensation Expense (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation	$6,660,000	$4,989,000	$2,279,000
Stock-based compensation expense due to modification	700,000	700,000	'
Total unrecognized compensation costs	13,000,000	'	'
Total unrecognized compensation costs, period of recognition	'2 years 8 months 12 days	'	'
Cost of revenues [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation	248,000	131,000	54,000
Research and development [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation	1,645,000	894,000	542,000
Selling and marketing [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation	1,783,000	827,000	533,000
General and administrative [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation	2,984,000	3,137,000	1,150,000
Performance Based Stock Options and Restricted Stock Units [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock-based compensation	$1,000,000	$300,000	'

StockBased_Compensation_Plans_6

Stock-Based Compensation Plans - Assumptions (Details) (Stock Options [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected term	'4 years 9 months 18 days	'5 years 2 months 12 days	'6 years
Expected volatility	51.00%	61.00%	59.00%
Risk-free interest rate	1.02%	0.76%	'
Risk free interest rate, minimum	'	'	1.05%
Risk free interest rate, maximum	'	'	2.65%
Expected dividend yield	0.00%	0.00%	0.00%

StockBased_Compensation_Plans_7

Stock-Based Compensation Plans - Employee and Nonemployee Stock-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Options granted, Shares	568,987	2,989,279	'
Capitalized stock-based compensation cost	$0	$0	$0
Recognized stock-based compensation tax benefits	0	0	0
Share-based and Nonemployee Services Transaction, Vesting Period	'6 months	'6 months	'
Stock-based compensation expense related to non-employee grants	500,000	800,000	'
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Options granted, Shares	543,987	2,860,927	1,305,620
Weighted-average grant date fair value	$6.75	$3.07	$5.65
Aggregate intrinsic value	6,800,000	6,000,000	5,700,000
Total fair value	4,900,000	2,100,000	900,000
Employee Restricted Stock Units (RSUs) [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Awards other than options granted, Shares	1,180,200	1,412,066	11,495
Weighted-average grant date fair value	$5.62	$5.70	$10.20
Fair value of the respective vesting dates	$1,400,000	$300,000	'

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'	'	'
Matching 401(k) contributions	$1.10	$0.70	$0.50

Income_Taxes_Domestic_And_Fore

Income Taxes - Domestic And Foreign Components Of Loss Before Provision For Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Domestic	($19,535)	($30,329)	($9,051)
Foreign	370	327	-504
Loss before provision for income taxes	($19,165)	($30,002)	($9,555)

Income_Taxes_Provision_For_Inc

Income Taxes - Provision For Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current provision:	'	'	'
Federal	$0	$0	$0
State	60	37	48
Foreign	61	170	0
Total current	121	207	48
Deferred provision (benefit):	'	'	'
Federal	0	0	0
State	0	0	0
Foreign	19	-66	0
Total deferred	19	-66	0
Total provision	$140	$141	$48

Income_Taxes_Reconciliation_Of

Income Taxes - Reconciliation Of The Statutory Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Tax at federal statutory rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	2.00%	-1.00%	-1.00%
Non-deductible permanent difference	-1.00%	0.00%	-3.00%
Change in valuation allowance	-34.00%	-34.00%	-31.00%
Research & development credits	-2.00%	1.00%	3.00%
Stock-based compensation	-1.00%	-1.00%	-5.00%
Other	0.00%	0.00%	2.00%
Provision for income taxes	-1.00%	0.00%	0.00%

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Disclosure [Abstract]	'	'	'	'
Net operating loss carryforwards	$45,401	$38,385	'	'
Research & development credits	2,335	2,703	'	'
Depreciation & amortization	583	312	'	'
Accruals & reserves	2,731	3,592	'	'
Deferred tax assets	51,050	44,992	'	'
Valuation allowance	-51,003	-44,926	-32,836	-29,231
Net deferred tax assets	$47	$66	'	'

Income_Taxes_Operating_Loss_Ca

Income Taxes - Operating Loss Carryforwards (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]	'
Unrecognized deferred tax benefits	$7.90
Federal [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net operating loss carryforward	121.3
State [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net operating loss carryforward	$108.20

Income_Taxes_Tax_Credit_Carryf

Income Taxes - Tax Credit Carryforward (Details) (Research Tax Credit Carryforward [Member], USD $)	Dec. 31, 2013
In Millions, unless otherwise specified	Dec. 31, 2013
Federal [Member]	'
Tax Credit Carryforward [Line Items]	'
Research and development credit carryforwards	$2.80
State [Member]	'
Tax Credit Carryforward [Line Items]	'
Research and development credit carryforwards	$3

Income_Taxes_Income_Taxes_Valu

Income Taxes Income Taxes - Valuation Allowance (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Movement in Deferred Tax Asset Valuation Allowance [Roll Forward]	'	'	'
Change in valuation allowance	$6,100,000	$12,100,000	'
Balance at Beginning of Year	44,926,000	32,836,000	29,231,000
Additions	6,077,000	12,090,000	3,605,000
Reductions	0	0	0
Balance at End of Year	$51,003,000	$44,926,000	$32,836,000

Income_Taxes_Unrecognized_Tax_

Income Taxes - Unrecognized Tax Benefits (Details) (USD $)	12 Months Ended
Income Taxes - Unrecognized Tax Benefits (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Beginning balance	$902,000	$824,000	$678,000
Additions based on tax positions related to the current year	2,023,000	78,000	146,000
Ending balance	2,925,000	902,000	824,000
Unrecognized tax benefits that would affect effective tax rate due to valuation allowance if recognized	$100,000	'	'

Net_Loss_Per_Share_Of_Common_S2

Net Loss Per Share Of Common Stock (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net loss attributable to common stockholders	'	'	'	'	'	'	'	'	($19,305)	($30,143)	($14,702)
Weighted average shares of common stock outstanding used in computing net loss attributable to common stockholders, basic and diluted	36,686,053	36,206,008	36,045,346	35,890,084	35,764,666	35,068,076	34,253,357	34,010,432	36,209,051	34,776,380	7,506,282
Basic and diluted net loss per share attributable to common stockholders (dollars per share)	($0.15)	($0.08)	($0.10)	($0.21)	($0.18)	($0.15)	($0.24)	($0.30)	($0.53)	($0.87)	($1.96)

Net_Loss_Per_Share_Of_Common_S3

Net Loss Per Share Of Common Stock - Outstanding Shares of Potentially Dilutive Securities (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount (Shares)	5,591,107	4,269,427	4,847,972
Options to purchase common stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount (Shares)	3,598,385	4,128,334	4,847,972
Restricted stock units [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount (Shares)	1,906,696	119,507	0
Common stock issuable pursuant to the ESPP [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount (Shares)	86,026	21,586	0

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Supplemental Cash Flow Information [Abstract]	'	'	'
Cash paid for interest	$0	$2	$69
Cash paid for income taxes	188	47	0
Changes in accounts payable and accrued liabilities related to property, plant and equipment purchases	-33	-100	147
Reclassification of warrant liability to additional paid-in capital upon initial public offering	0	0	921
Conversion of preferred stock into common stock upon initial public offering	$0	$0	$81,164

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	business_activity	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of business activities	'	'	'	'	'	'	'	'	1	'	'
Revenue	$35,841	$29,465	$26,338	$19,982	$18,597	$17,928	$22,265	$17,404	$111,626	$76,194	$68,144
North America [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	89,150	56,657	50,332
United States	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	83,700	54,700	47,500
International [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	22,476	19,537	17,812
Systems [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	61,359	39,145	46,552
Consumable Revenues [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	$50,267	$37,049	$21,592

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenue	$35,841	$29,465	$26,338	$19,982	$18,597	$17,928	$22,265	$17,404	$111,626	$76,194	$68,144
Gross profit	25,114	21,229	18,460	12,634	12,186	11,975	15,115	11,411	77,437	50,688	42,043
Net loss	($5,405)	($2,811)	($3,607)	($7,482)	($6,515)	($5,182)	($8,101)	($10,345)	($19,305)	($30,143)	($9,603)
Net loss per share attributable to common stockholders, basic and diluted (dollars per share)	($0.15)	($0.08)	($0.10)	($0.21)	($0.18)	($0.15)	($0.24)	($0.30)	($0.53)	($0.87)	($1.96)
Shares used in calculation - basic and diluted	36,686,053	36,206,008	36,045,346	35,890,084	35,764,666	35,068,076	34,253,357	34,010,432	36,209,051	34,776,380	7,506,282